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ABSTRACT 
 
Complement is comprised of a cascade of proteins that recognizes and attacks the 
invading microbes and thus is the first line of defense for the human body against 
invading pathogens. It is initiated via different activation pathways that lead to C3b 
deposition on the target and sequentially to the formation of lytic membrane attack 
complexes (MAC). One of the complement activation pathways – the alternative 
pathway (AP) – can be activated on any surface, self or non-self, and is therefore 
tightly regulated. Complement Factor H (CFH) is the most important complement 
down-regulator and it mediates target discrimination between self and non-self cells. 
Several point mutations in CFH and/or autoantibodies (AA) against it are found to be 
directly associated with atypical haemolytic uremic syndrome (aHUS), a severe and 
often fatal disease triggered by the impaired regulation of AP on self surfaces leading 
to complement attack.  
CFH is composed of 20 homologous complement control protein domains 
(CCP). The N-terminal domains 1 to 4 (CFH1-4) mediate inactivation of C3b on the 
self-surfaces and the C-terminal domains 19 and 20 (CFH19-20) are critical for the 
ability of CFH to discriminate between self and non-self structures. Self-surfaces are 
rich in anionic sialic acids (SA) and glycosaminoglycans (GAGs) that are not present 
on pathogenic microbes. CFH19-20 contains binding sites for both the C3d part of C3b 
and self-surface polyanions that enhance avidity of CFH to C3b on self surfaces and 
thus enhance C3b inactivation. CFH mutations that have been found in aHUS patients 
are mostly located in CFH19-20. 
 The previously solved X-ray crystal structure of CFH19-20 illuminated the 
location of aHUS related mutations. The aims of this thesis work were to study the 
functionality of CFH on a molecular level by studying the molecular structure of CFH 
C-terminus and its mutants along with structures of CFH in complex with its different 
interacting partners, as well as the structure of the domains of CFH-related protein-1 
highly homologous to CFH19-20. The structures solved and the their relevance are 
described in the four articles attached to this thesis. 
In the first article, stability of the CFH C-terminus fold by aHUS mutation(s) 
was studied by analyzing the binding of the CFH19-20 mutant proteins to C3d/C3b 
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using radioligand assays and affinity chromatography. The X-ray crystal structures of 
CFH19-20 with two different point mutations (of residues indicated to be involved in 
binding C3d/C3b) were solved. It was shown that these mutations did not result in the 
disruption of the basic fold of CFH19-20, but maintained the same fold with a 
prominent difference in the surface charge distribution in the zone of the residues. 
The results clearly indicated that the aHUS mutations on CFH do not disrupt the basic 
structural fold, but induce anomaly in the charge distribution of the molecule, 
explaining the effects of the mutations to its C3b/heparin binding abilities suggested 
to be critical for the pathogenesis of the disease. 
In the second article, we revealed the rationale of the molecular mechanism of 
CFH19-20 mediated self–nonself discrimination and showed why point mutations in 
CFH19-20 lead to aHUS. The CFH19-20 :C3d structure reported in this article revealed 
two independent binding interfaces between CFH19-20 and C3d, namely the ‘CFH19 
site’ and the ‘CFH20 site’. The results of deeper analysis of this structure also showed 
that the simultaneous binding of the CFH19-20 via the CFH19 site to C3b and via CFH20 
site to C3d was possible.  
In the third article, the X-ray crystal structure of CFH19-20 was solved in 
complex with the outer surface protein E (OspE) from Borrelia burgdorferi in order 
to understand the molecular mechanism of sequestering CFH by microbes which 
results in complement evasion. The nucleomagnetic resonance (NMR) structure of the 
OspE protein from Borrelia burgdorferi reported in this paper was required for 
solving the structure of OspE in complex with CFH19-20. Chemical shift perturbations 
studies using NMR also confirmed the physiological viability of the complex 
structure. This complex structure was the first structure of CFH19-20 in complex with 
any microbial protein and thus answered the puzzle of the molecular mimicry used by 
microbes involving CFH C-terminus in order to evade complement.  
In the fourth article the structure of the CFHR1 domains 4 and 5 (CFHR14-5) 
was solved and used to explain why AA bind to a common epitope on CFH domain 
20, which is highly homologous to domain 5 of CFHR1. The CFHR14-5 structure 
revealed an important structural bigamy of CFH and its related proteins that can be 
used to understand why CFHR-1 deficiency and formation of AA against CFH (CFH-
AA) lead to autoimmune aHUS (AI-aHUS). We extensively studied CFH-AA from 
more than a dozen of patients and their binding behavior to CFH and CFHR1. The 
results suggest a novel hypothesis on the pathogenesis of AI-aHUS. 
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In conclusion, the results have revealed the molecular mechanisms beneath 
different functionalities of the C-terminus of CFH. It is not only the most important 
molecule to facilitate the target discrimination by the AP, but is also a prominent tool 
used by the microbes in order to evade complement attack. Furthermore, the CFH C-
terminus also houses the AA binding epitope and thus also plays a role in the 
pathogenesis of AI-aHUS. We were also quite surprised to find out that the molecular 
structure of CFH C-terminus is extremely stable, and hardly undergoes any changes in 
its conformation in the presence of other ligands. Cumulatively, the structures of the 
CFH in presence of its different partners of interactions contributed greatly to the 
knowledge pool of the understanding of the molecular mechanisms associated with 
CFH in complement activation and regulation in health and disease. 
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1 INTRODUCTION 
 
The human body needs to protect itself both from invading pathogens as well as from 
the side effects of the immune processes going on inside the body. The continuous 
challenge thrown towards our body is both internal and external in nature. The 
security system our body puts up in order to handle these challenges is called the 
immune (coming from the latin word immunitas) system, which with evolution has 
developed into an organized, sensitive and a robust system. 
Our immune system can be classified into two parts, namely the innate and 
adaptive immunity. The concept of innate immunity shaped through evolution to 
discriminate self from non-self cells has been expanded, during the last decades, 
owing to the description of additional functions of the innate defenses. This part of 
immunity not only recognizes non-self molecules or surfaces, but also utilizes more 
sophisticated mechanisms of recognition. It is the type of immunity that provides the 
early line of defense against invading microbes and is comprised of the cellular and 
biochemical defense. Innate immunity is pre-poised to respond to an external attack 
even before they take place, but responds to repeated infections in a non-specific 
manner. On the contrary, the adaptive immune responses come into action by an 
exposure to external invading agents and increases its defense capabilities with each 
successive exposure to the particular microbe.  
 The most important components of the innate immune system are the 
epithelial barriers, phagocytic cells, dendritic cells, natural killer cells, cytokines and 
the complement system. The complement system was described in 1889 when Hans 
Büchner noticed a heat labile substance in blood serum which was able to kill 
bacteria, thus ‘complementing’ the action of adaptive humoral immunity. Paul Ehrlich 
first used the term “complement” by 1899 (1) for the phenomenon mentioned below 
in more detail.  
The mammalian complement proteins provide a first degree immune response 
against pathogens in blood and interstitial fluids (2). The primary aim of the 
complement system is to identify surfaces of bacteria, viruses and fungi, and also 
apoptotic host cells in order to be treated for cell lysis, clearance by phagocytosis and 
stimulation of the adaptive immune response.  
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Since 1960s, there has been a remarkable transformation in our understanding 
of the immune system and its functions. Advances in cell culture techniques and 
monoclonal antibody (mAb) production, immunochemistry, recombinant DNA 
technology, studies of molecule structures at atomic resolution employing different 
methods, and the generation of transgenic animals have changed the nature of 
immunological studies. Most of the immunological phenomena are now explained in 
structural and biochemical terms silently leading to revolutionary advances in the 
field.  
This thesis deals with different aspects of complement system and its occasional 
failure in case of the onset of infections or autoimmunity using X-ray crystallography 
as a tool to study it at atomic (or close to atomic) resolution. 
REVIEW"OF"LITERATURE""""""13!
 
2 REVIEW OF LITERATURE 
2.1 The complement system: an overview 
Innate immunity is the first-line of the immune defense system, essential for cellular 
integrity, tissue homeostasis and modifying the adaptive immune response. The innate 
immune system comprises of several components and uses several receptors for the 
recognition of microorganisms. A major humoral component of innate immunity is 
the complement system, which was established early in evolution and is the primary 
immune system in invertebrates. Complement was initially identified more than 100 
years ago as a serum component that ‘complements’ (thus contributing to the 
nomenclature) the antibody response towards pathogens (1,3). Now, more than a 
hundred years after these initial reports, the central role of this system in immune 
defense is much better known. It is now established as a system of a cascade of 
proteins and many of the biological effects of complement are understood in 
molecular terms and a role for complement in tissue homeostasis is emerging (2,4,5). 
Complement activation activates pro-inflammatory mediators, generates anaphylactic 
peptides, cytolytic compounds and antimicrobial compounds, recruits effector cells 
and induces effector responses. These proteins form a complex network of various 
recognition, effector, regulatory and receptor molecules that act in a finely tuned 
fashion, allowing complement to safely exert its functions (6,7). The activated 
complement system is beneficial for the protection of the host against invading 
pathogens (8). Other than protecting the host from infections by destroying and 
eliminating pathogens, complement maintains the integrity of the body by 
discriminating between healthy and injured tissue, in participating in the disposal of 
immune complexes and other cellular debris (9,10), also in inflammatory processes, 
angiogenesis and tissue regeneration (11,12). The individual complement reactions 
develop in a sequential manner, allowing regulation that modulates the intensity of the 
response and adjusts the effector functions for the specific immune response. It has 
also been established that complement is involved in the induction and regulation of 
both innate and adaptive cellular immune responses (2,13).  
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2.2 Activation of the complement system 
Complement can be activated via three primary pathways, the classical pathway (CP), 
the lectin pathway (LP), and the AP. All pathways converge at the central component 
C3 (Figure 1), which eventually initiates the terminal pathway forming the membrane 
attack complex (MAC) 
The CP is initiated by C1q binding to surface-bound immunoglobulins (Ig, 
mainly IgG1, IgG3 or IgM) or apoptotic cells (14-18). C1q is reported to bind to the 
Fc regions of the antibodies in order to initiate the CP (19). It has been suggested that 
binding of C1q to multiple, or even multimerized Ig, on a surface results in changes of 
the conformation of the C1-complex; this would prevent fluid phase antibodies from 
activating the cascade (20). Bacterial lipopolysaccharides, DNA, C-reactive protein 
(CRP), serum amyloid P component (SAP), and pentraxin 3 (PTX3) have been also 
found to activate the CP (21-25), but the physiological importance of these 
phenomena remains mainly elusive.  
The LP is activated by binding of mannose-binding lectin (MBL) to repetitive 
carbohydrates, or by binding of ficolins to carbohydrate or acetylated groups on target 
cell surfaces (26-28). MBL binds mannose and N-acetyl-glucosamine residues present 
in bacterial cell walls. The LP activation starts with association of two C1r- and C1s-
like MBL-associated serine proteases (MASP-1 and MASP-2) with MBL. 
Complement components C4 and C2 are both cleaved by MASP-2 leading to 
complement activation (29-31). MBL and C1q are structurally related but MBL 
possesses carbohydrate-binding lectin domains which is not present in C1q (32). LP 
can be also be activated by M-, L-, and H-ficolins (also called 1-, 2- and 3-ficolins), 
respectively. All of these ficolins function as pattern recognition molecules that 
recognize carbohydrates on microbial surfaces (28).  
The AP is spontaneously activated by the hydrolysis of the internal thioester 
group of C3 eventually forming the C3 convertase (classical/lectin pathway C3 
convertase C4b2aand the AP C3 convertase C3bBb). (17,33). This complex cleaves 
fluid phase C3 to C3a (a small 9 kDa inflammatory mediator) and C3b, an opsonin 
that deposits on the surface of target cells and particles and promotes phagocytosis. 
(34-38). This spontaneous complement activation in fluid phase, a unique feature of 
AP, is constantly targeting all surfaces that are devoid of sufficient down-regulators. 
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The larger fragment C3b formed as a result of C3 cleavage can also form 
additional C3 convertases with Bb and amplify complement activation. The cleaved 
C3b exposes a thioester group that can bind covalently to a target surface similarly to 
C4b in CP. At this stage the interaction between C3b and either factor B or CFH 
forms the basis of the self vs. non-self discrimination of AP (39,40). The 
amplification of AP occurs at this stage when C3 convertase activates more fluid 
phase C3 by cleavage to C3b (41). This amplification step causes effective C3b 
opsonization of the target (42,43). C3b can also bind to an already existing C3 
convertase, to form the C5 convertase which cleaves C5 and activates the terminal 
complement pathway. This activation of C5 potentially leads to inflammation (via 
C5a generation) and results in the lysis of the target cell through the formation of 
membrane pores by the MAC (44). Whereas these activation processes are needed on 
microbial surfaces, they are destructive to host (self) cells.  
Figure 1. Complement activation pathways and the regulatory role of complement factor H.  
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2.3 Regulation of the complement system 
The complement activity is important in our body for the clearance of foreign and 
altered host cells, whereas on the other hand, this activity must be well controlled in 
order to avoid self tissue damage. The spontaneous activation of AP as well as its 
secondary activation via the ‘amplification loop’ of classical/lectin pathway makes its 
regulation extremely important. Consequently, the process of complement activation 
is strictly regulated by membrane-bound and blood-plasma regulatory molecules that 
protect against complement activation by down-regulating the central proteolytic 
activity of the amplification and opsonisation steps. Deficiencies or mutations in 
complement regulators may predispose individuals to infectious and immune-related 
diseases or may lead to excessive complement activation and tissue injury. 
The complement system with its casacade of regulatory proteins may act 
during activation, amplification and effector steps of the cascade that enables fine-
tuning of the activation in different physiological circumstances. These proteins 
compete with other complement components for the binding sites. 
 The regulators of complement activation (RCA) gene cluster in chromosome 
1 encode several complement regulatory proteins (45-50). All the RCA proteins are 
composed of several homologous domains that have probably arisen by gene 
duplication events (51). These domains are approximately composed of 60 amino 
acids each and these protein domains are arranged in a bead-like structure. These 
short consensus repeat domains (presently known as CCP domains) are generally 
arranged in proteins in a head-to-tail fashion resembling beads-in-string (52). The 
binding sites in CCP-bearing proteins may span over its domains and therefore the 
orientation of the CCPs is critical for the proteins to act. These RCA proteins include 
C4b binding protein (C4bp), CFH, CFH-like protein-1 (CFHL-1), CFH-related 
(CFHR) proteins and membrane bound regulators complement receptor 1 
(CR1/CD35), membrane cofactor protein (MCP/CD46), and decay accelerating factor 
(DAF/CD55)(46-48).  
2.3.1 Soluble complement regulators 
C1 inhibitor (C1inh): C1inh is a 105 kDa serine protease inhibitor (serpin) with a 
heavily glycosylated single chain protein with a two domain architecture (53,54) 
which regulates the complement activation (via CP) by binding to C1r and C1s 
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causing their dissociation from C1q. It also influences the C activation in fluid phase 
by acting on C1 that otherwise could be spontaneously autoactivated by non-immune 
activators at low levels (55). Deficiency in C1inh results in hereditary angioedema 
(HAE), a disease characterized by recurrent acute edema of skin or mucosa which is 
associated with the lack of regulation of kallikrein by C1inh (56). 
 
C4b-binding protein (C4bp). C4bp is a 540-590 kDa protein consisting of several 
disulphide bonded subunits (57, 58) which interferes with the assembly of surface 
bound CP C3-convertase C4b2a by accelerating its decay. It also functions as a 
cofactor for factor I in cleavage of both surface bound and fluid phase C4b to C4c and 
C4d (59).  
 
CFH and its family. CFH is an elongated, approximately 155 kDa single-chain 
glycoprotein (60) consisting of 20 CCP domains (61)(Figure 2). When bound on the 
surface, CFH regulates AP indirectly by acting as a cofactor for the inactivation of 
C3b by factor I (62). It also directly inhibits the formation of C3-convertases by 
interfering with the binding of FB to C3b (39) and furthermore increases the pace of 
the natural decay of already formed AP convertases (63,64). Mutations in CFH have 
been associated with aHUS (65,66), dense deposit disease (DDD, also known as 
membranoproliferative glomerulonephritis type II or MPGN II ) (67). CFH has been 
found to have some of its polymorphisms (68) associated with aHUS as well (69). 
One of the CFH polymorphisms also has been associated with age related macular 
degeneration (AMD) (70,71). 
 Several other proteins from the RCA gene cluster have been found to have 
strikingly similar structural and functional features like CFH. These are all 
categorized in the family of CFH that will be discussed later. 
 
Properdin. Properdin exists in plasma as oligomers of two to four monomers linked 
together in a cyclic fashion (72). Each 52 kDa monomer consists of six 
thrombospondin repeat-domains (73). Properdin is the only positive regulator of 
complement activation that stabilises the nascent C3/C5 convertases of the AP and 
thus subsequently slowing down their rate of decay. (74).  
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Vitronectin. Also known as S-protein, vitronectin exists in at least two forms in 
plasma, a single chain molecule (84 kDa) or a double chain molecule where the 
subunits (69 kDa and 15 kDa) are linked together with disulfide bonds. It is also 
expected to form dimers and higher molecular weight aggregates in plasma (75). 
Vitronectin binds fluid phase C5b-7 in order to prevent its membrane-binding and 
thus prevent MAC insertion (76).  
 
Factor I. Factor I is a 90 kDa enzyme consisting of a 50 kDa and a 38 kDa chain 
linked together by a disulphide bond. (77,78). Factor I regulates the complement 
system by inactivating C4b and C3b molecules (with either CFH, C4bp, CR1 or MCP 
working as cofactors) (79-81). 
2.3.2 Membrane bound regulators 
CR1/CD35. This is a 205 kDa polymorphic protein and was first isolated from 
erythrocyte membranes. It regulates complement activation on cell surfaces and 
facilitates the decay of fluid phase immune-complexes (82,83). CR1 gene is located in 
the RCA cluster. 
 
Complement receptor of the Immunoglobulin family (CRIg). CRIg is a complement 
receptor expressed on tissue macrophages. It mediates opsonophagocytosis by 
binding C3b and inactive C3b (iC3b) on opsonized particles (84). CRIg regulates AP 
activation by binding to C3b and inhibiting the interaction of C3 and C5 with AP 
convertases (85). 
 
Decay accelerating factor (DAF or CD55). DAF regulates the AP and CP by 
accelerating the decay of C3-convertases (86). DAF is a 70 kDa membrane protein 
composed of four CCP domains and a serine/threonine/proline (STP)-rich linker (87).  
 
Membrane cofactor protein (MCP/CD46). It is 50-85 kDa heavily glycosylated 
membrane protein widely expressed on cells other than erythrocytes. It acts as a 
cofactor for C4b and C3b cleavage by factor I as mentioned before (81). MCP has 
four CCP domains and a heavily glycosylated STP region along with transmembrane 
and cytoplasmic domains as well (46).  
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CD59 (protectin). CD59 is a 18-20 kDa single chain protein expressed by RBC and 
other cells (88). This has five intra-chain disulphide bonds (89), heavily glycosylated 
and binds to the membrane associated C5b-8 complex preventing the unfolding of C9 
(90) and thus the membrane spanning by C9.  
2.4 The CFH family: focus on structure and functions 
CFH belongs to a protein family that also includes CFHL-1 (an alternative splicing 
product of the CFH gene) and five CFH-related proteins (CFHR) (91) (Figure 2). 
These proteins are composed of four to nine CCP domains, and share various degrees 
of sequence identity with each other and with CFH (Figure 2).  
2.4.1 Complement Factor H (CFH) and target discrimination 
CFH is the main soluble regulator of the AP (92). The CFH coding gene (CFH) is 
located in chromosome 1q32 within the RCA gene cluster (as mentioned before), 
adjacent to the five genes that code for the CFHRs. CFH is constitutively expressed in 
Figure 2. The schematic structure of factor H and its family members. For sequence 
identities of 32-49% the domains are displayed in white, for 57-84% identity in light blue, and 
for 85-100% identity in dark blue. The identity between the domains 3-5 of CFHR1 and 
domains 18-20 of CFH is indicated with percentages; *, sequence identity of the domain 3 of 
the basic isoform of CFHR1 is 100%, whereas that of the acidic isoform is 95% (216). CFH-
like molecule-1 (CFHL-1) is an alternatively spliced transcript from the CFH gene having four 
unique residues after domain 7. 
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the liver and is distributed systemically in body fluids. Reported CFH plasma 
concentrations vary, depending on the study population, age, genetic and 
environmental factors, as well as on the method used for quantification (93). Previous 
studies overestimated CFH concentration, which was a result of measuring both CFH 
and CFHRs. So, while early reports suggested that the plasma CFH concentration 
ranges 265–684 µg/ml (94) and 116–562 µg/ml (68), current studies using 
monoclonal antibodies have established mean CFH concentrations of 233 µg/ml (in 
young adults), 269 µg/ml (in elderly individuals) (95) and 263 µg/ml (93), in different 
healthy control populations with the age group between 25-66 (mean 42) years. Thus, 
normal CFH concentrations in human plasma correspond to approximately 1–2 µM. 
In addition, CFH is also produced outside the liver by different cell types such as 
monocytes (96), fibroblasts (97), endothelial cells (98), keratinocytes (99), 
thrombocytes (100) and retinal pigment epithelial cells (101). Locally released CFH 
in tissues may help to limit complement activation and maintain an anti-inflammatory 
environment. 
Each of the autonomously folding globular domains (see 2.3.1) is composed of 
about 60 amino acids and is stabilized by two internal disulfide-bonds (61). As 
mentioned earlier, CFH regulates complement activation by inhibiting the assembly 
of the AP C3 and C5 convertase enzymes via competition with FB for C3b binding; 
thus by facilitating the dissociation of the convertases by displacing bound factor Bb; 
and by acting as a cofactor for the serine protease factor I in the cleavage and 
inactivation of C3b (64,102). These regulatory activities are mediated by the four N-
terminal domains 1–4 of CFH (103,104)  (Figure 3), whereas the C-terminal domains 
19-20 are responsible for target recognition (Figure 3) (105-107). One of the 
important targets for CFH binding in the vicinity of C3b on host cells are polyanionic 
surface molecules, such as GAGs and SA, which increase the affinity of CFH for C3b 
(40). Thus, CFH is also able to control complement activation on self-surfaces (Figure 
2, also see section 2.5) (108,109). The target discrimination by AP is mediated by 
CFH and it has been established that the negatively charged polyanions or SA on the 
self cells contributes to higher CFH:C3b (surface) interaction and thus leads to high 
cofactor activity of CFH (39,40,64,110). In contrast, host-like polyanionic molecules 
are normally not present on the surface of pathogens, rendering them susceptible to 
complement attack. 
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In addition to C3b and polyanionic molecules, CFH interacts with several 
other endogenous ligands. These interactions allow CFH to regulate complement on 
certain host surfaces (such as the glomerular basement membrane, the extracellular 
matrix, and late apoptotic cells), which are otherwise not properly protected due to a 
reduced expression or the lack of membrane-anchored complement regulators (i.e., 
membrane cofactor protein, decay accelerating factor and CD59). Several of these 
ligands and structures activate complement via interactions with C1q, MBL, or 
ficolins. The simultaneous binding of both complement activating molecules (i.e., 
C1q, MBL) and molecules inhibiting the activation of complement (i.e., CFH, C4b-
binding protein) on such ligands and cells may facilitate their opsonisation and safe 
removal, but at the same time prevents an exaggerated complement activation that 
could lead to inflammation, unnecessary cell lysis, and subsequent tissue damage 
(111).  
Figure 3. Complement activation pathways and the regulatory role of factor H. The primary 
function associated with FH domains are also indicated. Sparsely dotted regions indicate 
(domains 6-7, domains 19-20) heparin and microbial binding sites while the densely dotted 
region (Domains 1-4) is associated with cofactor and decay acceleration activities.  
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CFH also binds to nonhost ligands, such as certain surface proteins of 
microbes, which hijack host CFH in order to protect themselves from complement 
attack (112). AP evasion by microbes is considered to the primary reason for the 
sequestering of CFH on their surface. Streptococcus pyogenes was the first microbe to 
be identified with this phenomenon to evade complement-mediated 
opsonophagocytosis (113-115). 
Most microbes acquire CFH via two regions of this control protein, domains 
5-7 and 18-20 (Figure 4). Domains 6-7 of CFH have been evidently functional in 
binding with Streptococcus and Neisseria surface proteins(114-119). Domain 18-20 
of CFH has been suggested to mediate Neisseria gonorrhoeae complement evasion 
via Por1A and Por1B (119-121). Borrelia burgdorferi also uses two different surface 
proteins for CFH binding, viz. OspE for binding domains 18-20 of CFH (122,123) and 
BbCRASPs for binding to  domains 6-7 (124,125). Some microbes such as Yersinia 
enterocolitica (126,127) and Streptococcus pneumoniae (128,129) have been shown 
to bind to non-conventional microbial binding domains in CFH. Interestingly, there 
are also microbes which have been found to bind CFH via two different domains 
using the same ligand on their surface, such as Pseudomonous aeruginosa (130) and 
Candida albicans (131,132). 
Sbi protein of Staphylococcus aureus and shiga toxin (Stx2) of 
enterohemorrhagic Escherichia coli have been reported to bind CFH in a non-
conventional manner. Sbi binds domains 19-20 of CFH by forming a tripartite 
complex with C3b (133), whereas Stx2 binds both CFH domains 6-7 and 18-20 in 
fluid phase (134). 
Several microbial ligands involved in CFH interactions have not been 
identified. For example, Haemophilus influenzae (135), Fusobacterium necrophorum 
(136), Aspergillus fumigatus (137), Bordetella pertussis, Bordetella parapertussis 
(138) and Onchocerca volvulus (139) have been reported to bind to CFH, but the 
bacterial ligands remain unknown. All of these microbes interact at least with CFH 
domains 6-7 and/or 18-20.  
2.4.2 The CFH like protein-1 
CFHL1 is a 43-kDa protein deriving from an alternative splice product of the CFH 
gene. It shares the seven domains (1-7) with CFH and has four additional C-terminal 
amino acids. As expected owing to high sequence similarity, CFHL1 possesses the 
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same complement regulatory activities as mediated by the N-terminus of CFH. 
CFHL1 may also play a role in age-related macular degeneration as the domain7 
harbors the site for Y402H polymorphism (see 2.7). Consequently, the CFHL1 402H 
variant has impaired ligand-binding capacity, similar to that exhibited by the CFH 
402H variant (140,141). However, an expression pattern differing from CFH and a 
distinct role in mediating cell adhesion have been reported for CFHL1 as well 
(142,143). CFHL1 has been observed to bind microbes which do not bind to CFH as 
well (144). 
2.4.3 The CFH related proteins 
The five CFHR proteins (CFHR1-CFHR5, Figure. 2) are from separate genes located 
adjacent to the CFH gene. They have domains homologous to the different domains 
of CFH, which are responsible for directing the complement regulatory activity of 
CFH to cell and tissue surfaces (91). These proteins have both similar and non-
redundant ligands and functions with CFH. CFHR1, CFHR3, CFHR4 and CFHR5 
bind to C3b, CFHR1, CFHR3 and CFHR5 to heparin, and CFHR4 and CFHR5 to 
CRP (145-151). In spite of similar cell and ligand binding properties, however, 
CFHR1 was reported to regulate the terminal complement pathway (145). In addition, 
it has been shown that both CFH and CFHR1 enhance neutrophil adhesion and 
activation during host cell-pathogen contact (152). Similar to CFH, CFHR4 binds to 
late apoptotic and necrotic cells, but in contrast to CFH, CFHR4 binds to the native 
pentameric form of CRP (153).  
2.4.4 Discrimination of self and non-self by CFH 
Identification of cell surfaces by the complement system is achieved by covalent 
binding of C3b molecules to the target surface through an exposed thioester in C3b 
that reacts with hydroxyl or amine groups. After initial binding of C3b or its homolog 
C4b by the initiation of complement cascade, the response (other than C4b2a) is 
amplified by enzyme complexes, or convertases, that form on the surface-bound C3b 
or C4b molecules.  
Host cells require soluble complement inhibitors, particularly CFH, which 
provide effective protection from unwanted complement-mediated damage, especially 
under conditions with strong complement activation. It is critical to protect 
noncellular surfaces, which do not carry surface-bound regulators. Several mutations 
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in the two C-terminal domains of CFH have been linked to aHUS (109). The same 
mutations also exhibited reduced functioning of CFH (154). Self-nonself 
discrimination by CFH is mediated by domains 19-20 that bind to surface-bound 
C3b/C3d and host surface GAGs or SA (155). Critical for target discrimination is the 
formation of a ternary complex of CFH domains 19–20, surface-bound C3b and 
GAGs or SA or C3d from the self-surface.  
Host cells, so-called non-activators of complement, possess cell surface 
polyanionic molecules that promote CFH binding (40). In contrast, complement 
activators such as microbes or rabbit erythrocytes that lack SA and host-like GAGs do 
not allow significant CFH binding and thus activates complement. Heparin is 
generally used in studies as a representative of host GAGs, and the major heparin 
binding sites are located in domains 7 and 20 (154-157). Polymorphisms or mutations 
in domains 7 and 19-20 may affect interactions of CFH with host cells and basement 
membranes, and are implicated in the diseases AMD and aHUS (106). 
2.5 CFH interactions with host ligands  
Other than its role as a complement regulator, CFH has been shown to mediate 
cellular interactions by binding to receptors on various cells as well. 
2.5.1 CFH interaction with C3b  
The central complement protein C3b is the main host ligand of CFH. The C3b-CFH 
interaction is of particular importance for the functions of CFH, namely complement 
regulation and host surface recognition. In CFH, four binding sites have been reported 
for C3b and its fragments, each with a different binding preference, affinity and 
functional relevance (155,158,159). These binding sites are located in the domains 1-
4, 6-8, 12-14 or elsewhere in domains 8-18, and 19-20. Solid evidence supports the 
two primary C3b binding sites in domains 1-4 and 19-20, whereas evidence for 
additional binding sites remains elusive.  
The N-terminal domains 1-4 mediate CFH binding to intact C3b, domains in 
the middle of CFH (domains 8-18) to the C3c part of C3b (i.e., binds both C3b and 
the C3c fragment), and domains 19-20 to the C3d part of C3b (i.e., binds both C3b 
and the C3d fragment) (159). Surface plasmon resonance (SPR) analyses indicate that 
the main binding sites are in domains 1-4 and domains 19-20, with the latter having 
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higher affinity (155), whereas additional domains may contribute to C3b binding. The 
crystal structure of the complex of C3b and CFH domains 1-4 showed that all four N-
terminal domains of CFH are involved in this interaction (160), and that these 
domains are necessary and sufficient for both cofactor and decay accelerating 
activities (160). 
 Thus, the deposited C3b and the surface GAGs (the latter absent on microbes) 
together allow CFH domains 19-20 to recognize the host cells.  
2.5.2 CFH attachment to host Cells  
In addition to membrane-bound regulators, host cells require soluble complement 
inhibitors, particularly CFH, which provide effective protection from unwanted 
complement-mediated damage, especially under conditions with strong complement 
activation (161). This is exemplified by the attachment of CFH to endothelial cells via 
cell surface GAG and C3b, as discussed above, which is impaired in aHUS and is 
associated with endothelial damage and acute renal failure (109,162). Also, CFH can 
bind to cell surface polyanionic molecules in the absence of C3b, although this 
binding is weak and not readily detectable in physiological buffers (109). Notably, 
this interaction is distinct from the binding to specific cellular receptors. 
Nonactivators of complement possess cell surface polyanionic molecules that 
allow for CFH binding (40). In contrast, complement activators such as microbes that 
lack SA and host-like GAG do not allow significant CFH binding and thus 
complement activation can proceed unchecked.  
Heparin is the highly sulfated form of heparan sulfate (HS) which contributes 
primarily to the negative charge of the endothelial cell surface glycocalyx and 
extracellular matrices, like the glomerular basement membrane (163). Soluble heparin 
is synthesized only in mast cells, but HS in the glycocalyx of the cells has heparin-
like domains where CFH is thought to bind.  
Chondroitin sulfate A (CS-A) is the main GAG on thrombocytes. Upon 
thrombocyte activation, the fully sulfated form of CS-A is exposed on the surface and 
is also released from α-granules (164). CFH also protects thrombocytes from 
complement attack (100). 
The prominent negative overall charge of self surfaces are mediated by the SA 
or neuraminic acids other than the GAGs. SA are a diverse group of nine-carbon 
saccharides with a negative charge that are present as terminal monosaccharide in 
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glycans of lipids and proteins (165). Sialic acid biology and specificity of the 
interactions with complement proteins are still poorly understood. 
The major heparin binding sites of CFH are located in domains 7 and 19-20, 
(155,166-169). Polymorphisms or mutations in domains 7 and 19-20 which affect 
their interactions with host cells and basement membranes lead to the pathogenesis of 
diseases AMD and aHUS. 
However, target surfaces bearing SA, especially erythrocytes, are recognized 
by CFH, which subsequently restricts complement activation on these surfaces 
(39,110). 
2.5.3 CFH binding to apoptotic and necrotic Cells  
To maintain tissue homeostasis, old and damaged cells must be removed and replaced 
by new ones, which is facilitated by apoptosis. Apoptosis is a programmed 
mechanism of cell death, involving changes like nuclear and cellular fragmentation, 
chromatin condensation and cell shrinkage. Changes in the cell membranes facilitate 
an efficient recognition and safe clearance of apoptotic cells by phagocytes. 
Complement proteins and pentraxins can bind to apoptotic cells and thus enhance 
their uptake by phagocytes via specific receptors (170). It has been shown that 
complement activation does not proceed to the terminal pathway on apoptotic cells, 
which is partly due to the binding of CFH (171). The loss of membrane-bound 
regulators on apoptotic cells is in part compensated by the acquisition of the soluble 
complement regulators CFH and C4b-binding protein (C4bp), protecting against 
complement attack that would otherwise lead to the release of potential autoantigens 
from the cells (172). The CFH binding site for apoptotic/necrotic cells is located 
within domains 6-20, which is outside the complement regulatory region (173). Thus 
surface-bound CFH is able to regulate complement activation. 
2.5.4 CFH interactions with Pentraxins  
Pentraxins are recognition molecules of the innate immune system. The classical short 
pentraxins CRP and serum amyloid P component circulate as pentamers in human 
plasma. The long pentraxins are comprised of the PTX3, PTX4 and neuronal 
pentraxins, which display a more complex structure (21).  
Human CRP is an acute-phase protein, whose synthesis by hepatocytes is 
upregulated in response to inflammatory stimuli. The main effector functions of CRP 
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are the activation of the complement system and the stimulation of phagocytosis 
(174). A direct binding of CFH to CRP has been described (175,176), suggesting 
down-regulation of CRP-mediated complement activation on self-surfaces by CFH. 
Later it has been shown that CFH mainly interacts with the monomeric or denatured 
form of CRP (153,177,178), although an interaction of CFH with native pentameric 
CRP at acute phase concentrations has recently also been demonstrated (179). The 
interaction of CFH with monomeric CRP leads to CFH recruitment, which limits 
complement activation but increases phagocytosis of apoptotic cells and reduces the 
release of inflammatory cytokines by macrophages (180).  
Aside from the short pentraxin CRP, CFH and C4bp were also shown to bind 
to the long pentraxin PTX3 (181,182). PTX3 has a pentraxin domain, homologous to 
that of the short pentraxins CRP and serum amyloid P, and has an additional unique 
N-terminal domain. In contrast to the short pentraxins that are mainly produced in the 
liver and thus act systemically in the body, PTX3 is produced locally by various cell 
types, such as vascular endothelial cells, fibroblasts, monocytes, macrophages, 
myeloid dendritic cells and neutrophil granulocytes (21). The binding of CFH to 
PTX3 requires the presence of calcium and is mediated by at least two binding sites in 
CFH. The primary binding site located within domains 19-20 of CFH interacts with 
the N-terminal domain of PTX3, whereas a secondary binding site on domain 7 binds 
to the C-terminal pentraxin domain (181).  
Cumulatively, the above-mentioned in vitro studies suggest that CFH binding 
to pentraxins is important to limit local complement activation and inflammation.  
2.5.5 CFH binding to extracellular matrix (ECM) 
It has been shown that the ECM proteins fibromodulin, chondroadherin, and 
osteoadherin can bind C1q and the regulators CFH and C4bp, which together 
maintain a balance between complement activation and inhibition (111). Exaggerated 
complement activation in turn may lead to inflammatory disease. Complement 
activation and the roles of CFH and C4b-binding protein on endothelial cell-derived 
ECM has been analysed in vitro. ECM-bound CFH and C4b-binding protein acted as 
cofactors for the inactivation of C3b and C4b, respectively. Furthermore, their 
binding and thus cofactor activity were enhanced by PTX3 (182). 
 
REVIEW"OF"LITERATURE""""""29!
 
2.6 Diseases associated with CFH family of proteins  
Any mishap in this complex enzyme cascade of complement system caused by 
complement gene mutations, AA or exogenous triggers may affect the balance 
between complement activation and inhibition, resulting in an attack on self tissue 
(13). Complement deficiencies and malfunctions in the complement system are 
associated with various infectious, inflammatory and (auto)immune diseases. CFH 
gene mutations and polymorphisms, as well as CFH-AA, are associated with several 
diseases that are characterized by severe complement dysregulation, e.g., the eye 
disorder AMD, the rare systemic diseases aHUS and DDD (91,183). Several studies 
in recent years (discussed below) clarified the roles of CFH and complement in the 
pathological conditions mentioned above.  
2.6.1 Age-related macular degeneration 
AMD is a leading cause of visual impairment in elderly populations. In recent years, 
complement gene mutations and polymorphisms have been found to be associated 
with AMD, pointing to a role of the AP activation in the pathogenesis of the disease 
(184). Although the underlying pathomechanism is not yet fully known, a role of 
complement-mediated inflammation in the eye is postulated. Correspondingly, several 
therapeutic compounds targeting the complement system are currently being 
evaluated in clinical trials (184). 
The common CFH polymorphism 402H has been identified as a major genetic 
risk factor for developing AMD (70,71,185,186). Functional analyses of the CFH 
402Y and 402H variants revealed a reduced binding of the AMD-associated 402H 
variant to murine CRP (157,187-190). Since residue 402 in domain7 is involved in the 
GAG-binding site of CFH, there are also subtle differences between the variants in 
their interaction with heparin and GAG-analogs (191,192). In contrast, the 402H 
variant has a higher affinity for DNA and necrotic cells compared to the 402Y variant 
(190). No difference in binding to retinal pigment epithelial cells was found (189), but 
the disease-associated variant binds less efficiently to both the extracellular matrix 
protein fibromodulin (190) and the Bruch’s membrane in the retina (191). In addition, 
malondialdehyde, a lipid peroxidation product, has been described as a novel ligand 
of CFH on apoptotic/necrotic cells, and shown to bind the 402H variant less strongly, 
thus adversely affecting the anti-inflammatory role of CFH (193,194). Very recently, 
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the rare CFH variant R1210C, previously described in aHUS patients, has been linked 
to AMD as well (195). This variant was shown to affect CFH interactions with C3b 
and cell surfaces (196). Altogether, these data suggest a CFH-associated defect in the 
proper, non-inflammatory handling of cellular waste and in the control of complement 
activation leads to damage retinal pigment epithelial cells. It is still unknown how 
these CFH defective functions cause or contribute to the late-onset disease AMD in 
affected individuals, and which other factors (genetic, environmental, lifestyle) 
influence the role of CFH (197).  
2.6.2 Dense deposit disease  
DDD, also termed membranoproliferative glomerulonephritis type II (MPGN II), is a 
rare renal disease that progresses to fatal renal failure in about 50% of patients. It is 
associated with uncontrolled AP activation in plasma that generates C3 activation 
fragments depositing in the glomeruli (198). In the majority of the DDD patients, C3-
nephritic factor, i.e. an autoantibody against the C3 convertase, is detected in serum 
(199). This factor causes enhanced complement activation by stabilizing the 
convertase or limiting down regulation of the convertase. In some patients, CFH 
mutations have been identified in these patients (183,200). These mutations may lead 
to CFH deficiency and thus insufficient plasma complement control (201). Mutations 
in cysteine residues that are important for forming the disulfide bonds within the 
single CCP domains can result in a defective protein folding and a CFH secretion 
defect (202). Moreover, a mutation in CCP4 was described, where the mutant CFH 
protein was inefficient in its cofactor activity, while cell-binding functions remained 
unaffected (67). All these cases led to a defective C3 activation control in plasma, 
either due to a quantitative CFH deficiency or dysfunctional CFH.  
CFH-AA have been described in DDD (203). So far, only one case has been 
published where the AA was characterized in detail. The isolated CFH ‘mini-AA’ 
consisted of lambda light-chain dimers that bound to CCP3 of CFH, i.e., within the 
complement regulatory region of the molecule (204). Functional assays demonstrated 
that the AA inhibited the CFH-C3b interaction and caused an increased C3 turnover 
due to a blockade of the complement inhibitory activity of CFH (203). Due to the lack 
of systematic screening for such AA in DDD patients, at present the prevalence and 
the characteristics of DDD-associated CFH-AA are not known. 
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2.6.3 Atypical haemolytic uremic syndrome (aHUS) 
The rare systemic disease aHUS is characterized by haemolytic anemia, 
thrombocytopenia (low platelet count) and impaired renal function (205). Its 
pathology is related to dysregulation of the AP, caused by polymorphisms, mutations 
and deletions in complement genes, or due to CFH-AA (206).  
CFH mutations affect approximately 30% of aHUS patients. More than 100 
CFH mutations have been described in aHUS patients and can be searched in an 
online database (http://www.fh-hus.org) (207). In most cases, these are heterozygous 
mutations affecting various domains of CFH. However, most of the mutations affect 
the C-terminal CCP domains 19 and 20. Functional analyses of several of these 
mutants showed an altered interaction with C3b, heparin and endothelial cells 
(196,208,209). Furthermore, gene conversion and gene deletions leading to hybrid 
CFH proteins with functionally affected C-terminal domains have been reported (210-
212). These data show a disturbance in the physiological interaction of CFH with host 
endothelial cells. Certain mutations in domain 20 were also found to reduce the 
binding of CFH to CRP (180). For many of these mutations, however, there is no 
functional effect known to date.  
CFH-AA of the IgG class are detected in approximately 10% of aHUS 
patients (213,214). This form of aHUS affects primarily juvenile patients. A further 
characteristic of this patient group is that >90% of the affected individuals lack the 
CFHR1 gene, indicating that this genetic defect predisposes to the development of 
CFH-AA (214-217). These AA can also occur together with mutations in the CFH, 
CFI, C3 or MCP genes (217). The antibody binding sites in several patients were 
determined using recombinant CFH fragments and it was observed that practically all 
patients have AA that bind to domains 19-20 of CFH, although in some cases 
reactivity with other domains was also seen, such as to domains 8-11 (214,217-219). 
In three patients anti-CFH IgA AA were found that similarly recognized domains 19-
20 (220). Functional studies indicated that the AA interfered with the recognition 
functions of CFH, namely, impairing its interaction with surface-bound C3b and 
inhibiting the CFH complement regulatory activity on host surfaces (218,220,221). 
This reduced protection from complement-mediated damage is likely to be involved 
in the endothelial injury associated with aHUS. Owing to the similarity in the C-
terminal domains of CFH and CFHR1, most of the studied AA recognise both the 
proteins. CFHR1 in fact can hijack AA and rescue host cells when added to CFH-AA-
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positive plasma (220). CFH-AA from healthy people have not been studied for 
obvious reasons, so the presence of CFHR1 and CFHR3 in these patients are not 
known. 
Altogether, these genetic and acquired abnormalities affecting CFH allow a 
normal fluid-phase regulation, but result in an impaired cell binding and cell surface 
protection from complement attack, which apparently contribute to the endothelial 
damage and microvascular thrombus formation in aHUS. However, further studies are 
needed to understand the role and relevance of mutations affecting other domains of 
CFH in aHUS. A recent study showed that some of the mutations do not lead to any 
known functional effect on CFH, thus care should be taken when interpreting genetic 
data and advising patients (222). 
2.7 The microbial complement evasion: role of CFH  
Since complement plays an important role in protection against infections, numerous 
viruses, bacteria, fungi and parasites have acquired the ability to sequester host 
complement regulators like CFH (112). Other than bacterial complement evasion 
(which is discussed here), viral complement evasion has been reported as well in 
different families of viruses. Herpesviridae and Coronaviridae are reported to 
interfere with CP, poxviruses and herpesviruses encode and express proteins with 
functional similarities to complement regulators (223). Viruses belonging to the 
families Poxviridae, Herpesviridae, Retroviridae and Togaviridae can incorporate 
host complement control proteins in their viral envelope and/or upregulate expression 
of these proteins in infected cells (224). It must be mentioned here that CFH has not 
yet been reported to have a direct involvement in any viral complement evasion. One 
of the vaccinia virus complement control protein has a striking similarity with domain 
16 of CFH (225).  
As a common theme, it appears that many of the microbial CFH binding 
proteins interact with the domains 6-7 and 19-20, the primary CFH domains relevant 
for host cell recognition (Figure 4) (226). It has been suggested that the CFH Y402H 
polymorphism may be associated with enhanced resistance to certain bacterial 
infections. The AMD-associated CFH 402H variant has a lower binding affinity to 
various group A streptococci compared to the 402Y variant, resulting in more 
efficient opsonization and phagocytosis (227,228).  
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However, studies indicate that microbes may use CFH for purposes other than 
complement inhibition, such as mediating entry into host cells as well. The interaction 
of CFH with neutrophils in the context of host-pathogen interactions is being 
characterized (152). CFH, when bound on the human pathogenic yeast Candida 
albicans, served as a bridging molecule to enhance the adherence and antimicrobial 
activity of neutrophils. The CFH-CR3 interaction could enhance Streptococcus 
pneumoniae adherence and uptake by epithelial cells and neutrophils (229). Similarly, 
CFH facilitated the adherence of Neisseria gonorrhoeae to human CR3-transfected 
cells (230). These data indicate a role for CFH in cellular adhesion by interacting with 
CR3, even beyond pathogen-host cell interactions. 
Binding of CFH downregulates opsonization and prevents further 
amplification of the C cascade and formation of cytolytic MAC. While prevention of 
opsonization and subsequent phagocytosis is beneficial for practically all microbes, 
evasion of MAC formation is especially important for Gram-negative bacteria and 
spirochetes that have an outer membrane exposed to plasma and therefore vulnerable 
to MAC attack.  
The molecular mechanism of CFH sequestration by Neisseria meningitidis has 
been demonstrated by the FHBp:FH complex structure (118). It has been observed 
that some microbes utilize the other microbial binding site on domains 19-20 of CFH 
to evade complement attack. Some microbes have also been shown to use two 
microbial evasion sites of CFH (domains 6-7 and 19-20). For instance, B. burgdorferi 
sensu stricto, which causes Lyme disease, binds CFH via domain 7 using protein 
CRASP-1 and potentially other CRASPs (231) and via domains 19–20 using OspE 
and its paralogs (122). Borrelia hermsii is known to bind CFH using FhbA in order to 
evade complement attack (232). Leptospira interrogans is known to bind both CFH 
and CFHR1 via LfhA (233). Recent reports have confirmed the binding of Salmonella 
enterica to CFH via Rck protein (234). 
2.8 Anti-FH autoantibodies and aHUS 
AA to CFH have been reported in aHUS and DDD patients and are associated with 
the diseases (see 2.6.2 and 2.6.3). However, a clear understanding of the mechanisms 
of how AA contribute to endothelial cell damage along with the pathophysiology of 
aHUS is still elusive. AA to CFH in HUS patients were first reported in 2005 for three 
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children of the French aHUS cohort. The AA-positive plasma inhibited binding of 
CFH to the C3bBb convertase, but did not affect the complement regulatory functions 
of CFH in fluid phase mediated by the N-terminal domains 1–4 of CFH (213). 
CFH-AA were later on reported in five additional patients, and their binding 
epitopes were localized to the C-terminal cell surface attachment region of CFH, to 
domains 19–20 (218). These AA do not inhibit the complement regulatory activity of 
CFH in fluid phase but block cell binding of CFH. Purified IgG AA of the patients 
reduced C3b binding of CFH, blocked binding of CFH to cell surfaces and inhibited 
haemolytic activity (218). 
The frequency of CFH-AA has been analyzed in different cohorts 
(213,214,216-218). This suggests a similar mechanism of AA and of C-terminal 
mutations in CFH. Consequently, it was hypothesized that these AA inhibit surface 
attachment and the complement regulatory functions of CFH on cellular surfaces 
(235).  
 Protein analyses of the CFH-AA-positive plasma samples demonstrated the 
complete absence of CFHR1 and CFHR3 (214). Further detailed analyses showed for 
14 patients the complete absence of both plasma proteins and for two patients rather 
low, barely detectable protein levels (235). Genetic analyses showed for the 14 
deficient patients the complete absence of CFHR1 and CFHR3 due to a homozygous 
deletion of a large 84 kb genomic fragment which includes the CFHR1 and CFHR3 
genes (Figure 5). The AA of practically all patients with AI-aHUS recognize the C-
terminus of CFH, and inhibit the protective activity of CFH against complement 
attack to host cells (214,218,221).  
The reason for the association between CFH-AA and the CFHR1 deficiency is 
not yet known. An infection often precedes emergence of CFH-AA (236), and it is 
known that a wide variety of microbes recruit host CFH onto their surface via domain 
Figure 5. Schematic diagram of the chromosome 1, region q32. The 20 domains of 
CFH, the five domains of CFHR3, the five domains of CFHR1, and the nine domains of 
CFHR4 are indicated by vertical bars. The position of the two duplicated homologous 
segments (B and B’) is shown in purple and orange boxes. Failure of DNA amplification 
downstream reveals a deletion of a genomic ~84kb fragment of CFH in 99% of the AA-
HUS patients.  
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20 of CFH, known as the common microbial binding site, to prevent complement 
attack (226). The association of CFHAA with any physiological or microbial ligand 
binding to CFH19-20 and the location of the binding sites of the AA within CFH19-20 
have not, however, been shown. 
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3  OBJECTIVES 
 
 
 
To characterize the structure-function relationship of the C-teminus of CFH via 
three distinct objectives: 
 
I. To identify the molecular mechanism of the self non-self discriminatory 
process by CFH, and its implications on aHUS mutations. 
II. Structural basis of complement evasion by microbes using CFH20: 
Borrelia as a case study. 
III. Connecting CFHR1 deficiency and AI-aHUS using a structural approach. 
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4 MATERIAL AND METHODS 
4.1 Materials 
4.1.1 Proteins  
Generation of the recombinant proteins generated specifically for the studies of this 
thesis by the author are described below in section 4.2. 
Wild-type CFH19-20 was cloned without expression tags by Maria Pärepalo. 
The mutants R1203A and Q1139A used in study I were cloned and expressed by 
Markus J. Lehtinen. The CFH19Del-20 (Q1137A/ Q1139A/ Y1142A) and CFH19-20Del 
(T1184G/ K1202A/ R1203A/Y1205A) used in study II were cloned, expressed and 
purified by Markus Lehtinen and Satu Hyvärinen. The C3d with its residue C17 (the 
thioester forming residue) mutated to alanine and the C3dg (along with the mutants 
D36A, E37A, E117A, D122A, E160A, D163A, and K291A) used in the study I and II 
respectively were cloned and expressed in E. coli and were procured from Prof. David 
Isenman’s lab (Toronto, Canada) (237,238). 
Rabbit polyclonal antibodies against CFH19-20 and CFH, and monoclonal anti-
CFH19-20 antibody VIG8 (239) were received from Dr. Jens Hellwage (Jena, 
Germany). The mAb C18 (107) was purchased from Enzo Life Sciences (Lörrach, 
Germany). 
For NMR, OspE (residues 21-171) was cloned, expressed and purified with a 
His-tag in Dr. Hideo Iwaï’s lab. The GST-tagged OspE used for crystallization was 
cloned by Mia Eholuoto (122). 
4.1.2 Microbial strains used 
Cloning of the CFHR14-5 constructs was done in E. coli XL10-Gold® cells 
(Stratagene) and the expression of CFH19-20 proteins in Pichia pastoris X-33 strain 
(Invitrogen).  
The construct of OspE used for NMR was cloned in XL10-Gold cells and was 
expressed in E. coli ER2566 strain grown in M9-medium. 
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4.1.3 Bioinformatical resources used 
The following web resources were used to obtain sequence and structure information: 
European Bioinformatics Institute (www.ebi.ac.uk), National Center for 
Biotechnology Information (www.ncbi.nlm.nih.gov), Protein Data Bank 
(www.rcsb.org/pdb), and “Proteins, Interfaces, Structures and Assemblies (PISA) 
server” (http://www.ebi.ac.uk/msd-srv/prot_int/) of the European Bioinformatics 
Institute. 
4.1.4 Patient material used 
Sera were collected from aHUS patients with CFH-AA in Germany and Hungary. The 
studies have been approved by the Research Ethics Committee of the Medical Faculty 
of Friedrich Schiller University and were performed in accordance with the 
declaration of Helsinki.  
4.2 Methods 
4.2.1 General laboratory methods for proteins 
The proteins were resolved based on their size using standard sodium dodecyl sulfate 
– polyacrylamide gel electrophoresis (SDS-PAGE) techniques and visualized using 
staining with Coomassie Brilliant blue, silver staining, or by performing Western 
blotting where detection was done with primary antibodies and horseradish 
peroxidase-conjugated secondary antibodies (Jackson Immunoresearch). Protein 
concentrations were measured using absorbance at 280 nm wavelength, BCA assay 
(Thermo Scientific), and comparing intensity of the protein bands with a standard in 
the gel using Image J program (http://rsb.info.nih.gov/ij/). Buffer exchanges were 
performed using dialysis membranes or PD-10 buffer exchange columns (GE 
Healthcare). 
4.2.2 Protein iodination 
For radio immune assays (RIA) or radio ligand assays (RLA) proteins were iodinated 
using the Iodogen method in a hood of a class B radioactive work area (240). Iodogen 
tubes were prepared by mixing Iodogen to chloroform and dried. Iodination was 
performed by incubating 20-100 µg of protein with 0.2-1.0 mCi of 125-I for 10-20 
minutes in PBS. After the reaction the mixture was transferred to a glass tube for 
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unreacted iodine ions to form molecular iodine I2. The free iodine was separated from 
proteins using PD-10 buffer exchange columns. The specific activity of the proteins 
was typically 1.0 – 4.0 x 106 cpm/µg (16.7 – 66.7 kBq/µg). 
4.2.3 Expression and purification of GST-OspE used for X-ray crystallography 
The recombinant GST-OspE fusion protein was expressed in E. coli BL21(DE3)RIL 
host cells. Briefly, a primary culture was started by inoculating a single colony from a 
fresh transformant plate to 50 ml of Luria-Bertani (LB) broth containing 100 µg/ml 
ampicillin. The culture was incubated at 37°C with shaking overnight. The culture 
was diluted 1:50 with 1500 ml of LB broth containing 100 µg/ml ampicillin and 
incubated at 37°C for 3 h, until the growth reached the mid-log phase with an optical 
density of 0.6 at 600 nm. Isopropyl-β-D-thiogalactoside (IPTG) was added to a final 
concentration of 0.7 mM. After an additional incubation of 3 h, the cells were 
harvested, washed, and sonicated. The GST-OspE fusion protein was purified by 
affinity chromatography on glutathione-sepharose matrix according to the instructions 
of the manufacturer (GE Healthcare). The recombinant OspE was cleaved from GST 
with bovine thrombin (Sigma) in thrombin cleavage buffer (150 mM NaCl, 100 mM 
KCl, 2.5 mM CaCl2, 1 mM dithiothreitol, 20 mM hepes, pH 7.6) for 3 h and then 
eluted with thrombin cleavage buffer. The cleaved OspE was dialyzed against 20 mM 
Tris-buffer containing 20 mM NaCl, pH 7. The purity of the OspE protein after the 
elution from the glutathione-sepharose beads was confirmed by SDS-PAGE analysis. 
4.2.4 Cloning of the CFHR1 C-terminus domains 
Since the C-terminus (domains 4 and 5) of CFHR1 is different from CFH19-20 only by 
2 residues, we decided to generate the CFHR1 C-terminal construct by mutating the 
two residues of the CFH19-20 construct, S1191L and V1197A. Mutagenesis was done 
using QuikChange Multi site-directed mutagenesis kit (Stratagene). The primers were 
designed based on the criteria presented by the manufacturer of the mutagenesis kit 
and were obtained from Sigma-Aldrich (sequences given in study IV). The pPICZαB 
vector (Invitrogen) with the inserted CFH19-20 sequence was used as a template in 
mutagenesis PCR reactions, and then expressed in E. coli. The clones were selected 
using Zeocin® (InvivoGen) antibiotic selection on Luria-Bertani medium and then 
sequencing from 3’ and 5’ ends over the CFH19-20 region in the Haartman Institute 
sequencing core facility. The plasmids harboring the mutation(s) were transferred to 
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Pichia pastoris for expression using electroporation according to manufacturer’s 
instructions (BioRad). The transformed cells were selected using Zeocin® and small 
scale culture expression in 10 ml. The media was screened for the presence of the 
protein using Western blotting with polyclonal anti-CFH19-20 antibody cross-reacting 
with CFHR-1. The clones that were recognized by the antibody and had the highest 
expression level were selected for large-scale expression. 
4.2.5 Expression and purification of CFHR14-5  
The CFHR14-5 protein was expressed using the Pichia pastoris expression system as 
described by the manufacturer (Stratagene). All the incubation steps were performed 
at 28°C under continuous shaking (225 rpm). Initially 5 ml of Buffered Methanol, 
Glycerol, Yeast extract (BMGY) medium with 100 µg/ml of Zeocin® was inoculated 
and incubated for approximately 17 hours, which was used to inoculate 50 ml of pre-
tempered BMGY medium that was incubated for 16 hours. The cells were harvested 
by 5 min centrifugation at 3000 g at 22 °C. The cells were suspended to 1 liter of 
Buffered Methanol Medium (BMM) medium for expression. Ten ml of methanol was 
added to the culture after 24 hrs and 48 hrs of expression, which was stopped after 72 
hrs. The supernatant was collected after centrifuging the cells at 5000 g for 15 min. 
The supernatant was filtered using 0.8 µm/0.2 µm filters. The pH of the filtrate (pH < 
5) was adjusted to 6.0-6.5 with Na2HPO4 and diluted 1:1 with H2O. The proteins were 
purified from the filtrate using 1 ml Hi-Trap heparin columns (GE Healthcare) and 
eluted with 1 M NaCl in phosphate buffered saline (PBS: 137 mM NaCl, 2.8 mM 
KCl, 9.7 mM phosphate, pH 7.4). The protein preparations were further purified with 
Sephadex 75 (10/300 GL) gel filtration column using the ÄKTA® purifier system 
(GE Healthcare). 
4.2.6 Light scattering and size exclusion chromatography analysis  
Size exclusion chromatography coupled with multi angle light scattering (SEC-
MALS) was used to find the optimal proportions of CFH19-20 and OspE to form the 
complex in solution (Supplemental Fig 1b in study III). The proteins alone and their 
mixtures in two different apparent molar ratios (1:1 and 1:1.25) were run over a 
Superdex200 column attached to HPLC equipment (Shimadzu). MiniDAWN TREOS 
light-scattering detector and Optilab rEX refractive index detector together with 
ASTRA 5.3.4.20 software (Wyatt Technology Corporation) were used to calculate 
MATERIAL"AND"METHODS""""""41!
 
masses of proteins and complexes eluted from the column. A size exclusion analysis 
of OspE and CFH19-20 alone and the OspE:FH19-20 complex was done by running the 
preparates through a Superdex200 column attached to an ÄKTA purifier HPLC 
system (GE Healthcare) (Fig. 2a  of study III). All samples were eluted in PBS at 0.5 
mL/min flow rate at 22˚C. 
4.2.7 Generation of C3b 
The C3b protein (used in study I) was prepared from plasma purified C3 (kindly 
provided by Karita Haapasalo-Tuomainen) using trypsin cleavage. First, 1 mg/ml of 
C3 in PBS was warmed in a water bath to 37 °C. Trypsin (Sigma- Aldrich) was added 
to the solution to make it 1 % (w/v), mixed, and incubated for 3 min. Soy bean trypsin 
inhibitor SBTI) (Sigma-Aldrich) was added to the solution to make it 2 % (w/v) and 
mixed to stop the reaction. The result was monitored with SDS-PAGE gel analysis, 
where a shift in the alpha chain of C3 indicated cleavage of C3a from C3 and 
generation of alpha’-chain. Trypsin, SBTI, C3a, and C3b were separated with HiLoad 
16/60 Sephadex 200 gel filtration column attached to an ÄKTA® purifier system. 
4.2.8 Radioligand assays 
The proteins were attached to Nunc Polysorp Break Apart plates at 5-20 µg/ml in 
0.5X PBS (68.5 mM NaCl, 1.4 mM KCl, 4.85 mM phosphate, pH 7.4) by incubating 
for 17 hours at 4°C. The wells were blocked with 0.5 - 2.0 % bovine serum albumin 
(BSA, Sigma-Aldrich) in 0.5X or 1X PBS for 2 hours at 22°C and washed 1-2 times 
with 0.5X or 1X PBS. In inhibition experiments the radioligand and inhibitor were 
usually premixed. In direct binding experiments the radioligand was pipetted onto the 
wells bearing the ligand. The plates were incubated for 2 - 3 hours at 22 °C and 
washed with ice cold 0.5X or 1X PBS once or twice. The radioactivity of the 
separated wells was measured with a Wizard gamma counter (Perkin-Elmer). 
4.2.9 Surface plasmon resonance 
SPR assays were performed on a Biacore 2000 equipment using carboxymethylated 
dextran chips CM4 and CM5 (GE Healthcare) .  
4.2.10 Heparin affinity chromatography 
Heparin affinity chromatography was performed with the ÄKTA® purifier system 
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(GE Healthcare) and Hitachi LaChrom HPLC (Merck). The proteins were injected 
into a 1 ml Hi-Trap Heparin column (GE Healthcare) in 0.5X PBS and eluted using a 
linear salt gradient up to 0.5 - 1.0 M NaCl in PBS. The elution was monitored using 
absorbance at 280 nm. The elution fractions were verified using anti-CFH19-20 
antibodies by Western blotting. The ionic strength of the elution buffer was monitored 
in real time with a conductivity meter in ÄKTA® or measured from the elution 
fractions using a conductivity meter CDM210 (Radiometer Analytical SAS). 
4.2.11 X-ray crystallography 
The proteins to be crystallised were purified to 99 % purity and were handled using 
robotic protein dispensers in order to set up the initial crystal screens. All of the 
crystallographic experiments and structure determination were performed in Prof. 
Adrian Goldman’s laboratory in the Institute of Biotechnology, Helsinki. 
 Both the CFH19-20 constructs with a single point mutation, either CFH19-
20Q1139A or CFH19-20R1203A, were crystallised at 22°C using 2M ammonium sulphate as 
a precipitant in 0.1 M Bis-Tris buffer, pH 5.5 or pH 6.5, respectively. X-ray data for 
both mutants were collected at beam line ID14-3 at 0.931Å wave-length in the 
European Synchrotron Radiation Facility (ESRF), Grenoble, using a ADSC Quantum 
4 CCD detector. The data for both of the mutant protein crystals were collected at 100 
K. The crystals belonged to the tetragonal space group I4122 (Table 1) with one 
molecule per asymmetric unit and a solvent content of approximately 68–70%. The 
CFH19-20Q1139A crystals diffracted to 1.9 Å resolution and the CFH19-20R1203A crystals to 
1.52 Å resolution (Table 1). The structures were solved using molecular replacement 
with MOLREP (241) and refined with REFMAC5 (242,243) with manual rebuilding, 
as necessary, in COOT (244). The final structures were refined using PHENIX (245) 
program “phenix.refine” with the alternative conformations. The crystals contained 
also sulphate molecules, as expected, and six of those per CFH19-20Q1139A molecule 
and two per CFH19-20R1203A molecule were also built similarly. The final work and free 
R-factors were 20.4% and 24.5% (CFH19-20Q1139A) and 20.3% and 22.2% (CFH19-
20R1203A) with acceptable geometry, and there were no chain breaks in the models 
(Table 1). 
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 Despite extensive trials, we were unable to crystallize non-mutated CFH19–20 
with C3d, because CFH19–20 always crystallized by itself as a tetramer (study I) (106) 
in various crystal forms. We performed a small crystallographic trial with 7 of the 
CFH19–20 mutants in different pH to identify the mutant which did not crystallise very 
easily in presence of 2M ammonium sulphate (Table 2). We found the double mutant 
CFH19–20D1119G/Q1139A did not yield any crystals in the offered conditions. From this 
experiment, we reasoned that inhibiting tetramer formation would help crystallization 
of the complex, and therefore, we used this CFH19–20 double mutant for the rest of our 
crystallographic experiments in order to break the tetramer interface. The mutant still 
bound C3d well but crystallized poorly by itself. This allowed us to crystallize CFH19–
20D1119G–Q1139A:C3d complex because the homotetrameric crystals did not form. Small-
angle X-ray scattering (SAXS) data also showed that the CFH19–20D1119G–Q1139A mutant 
is clearly monomeric, whereas the WT protein has a tendency to form higher 
oligomers and aggregates. The CFH19–20D1119G–Q1139A:C3d complex was crystallized at 
22 °C from 0.1 M Hepes, pH 7.5, containing 14% PEG 4000 (160 µM CFH19–20, 
200 µM C3d). Crystals appeared in 3–4 d. All data were collected at the European 
Synchrotron Radiation Facility (ESRF). The initial dataset, to 3.8-Å resolution, was 
collected at ID14-2; optimization of cryo-cooling conditions with 10% glycerol 
enabled us to collect data to 2.3-Å resolution at ID23-1 (Table 1). The initial 
molecular replacement solution was found with the 3.8-Å data. PHASER (246) 
Table 2. Crystal screen set up with seven CFH19-20 mutants in order to see their 
crystallising behaviour in different pH. CFH19-20D1119G/Q1139A did not crystallise in any of 
them. The proteins were in 20mM Tris and 20mM Nacl. All of the crystallasing solutions 
contained 2 M ammonium sulphate as a salt precipitant. 
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readily found two molecules of C3d but not CFH19–20. However, closer inspection of 
Fo–Fc and σA-weighted maps revealed very clear features of continuous extra density 
consistent with a single CFH19–20, and therefore, we manually built CFH20 into the 
density between the two C3d molecules, giving an asymmetric unit with two C3d 
molecules and a single CFH19–20. Successive rounds of building with Coot (244) and 
refinement with REFMAC (242,243) or PHENIX (245) against the 2.3 Å dataset 
allowed us to build an essentially complete model of the full heterotrimeric complex. 
The R factors (Rwork/Rfree) were 20.4%/24.3% with good geometry (Table 1). 
Since CFH19-20 tends to crystallize as a homotetramer as stated above, we used 
CFH19–20D1119G–Q1139A mutant for the crystallization experiments to prevent this from 
happening, as before. The CFH19–20D1119G–Q1139A mutant protein has similar binding 
affinity for OspE as the wild type CFH19-20 (mean IC50 of 0.55 vs. 0.42 µM) 
(Supplemental Fig 4 of study III). The CFH19–20D1119G–Q1139Amutant:OspE complex 
was crystallized at 293 K from sitting drops in the presence of 2 M ammonium 
sulfate, 0.1 M citric acid, and 0.2 M sodium chloride at pH 5.5. Crystals appeared 
within 4 days and were cryo-protected in the mother liquor supplemented with 25% 
glycerol. The diffraction data (to 2.83 Å) were collected at ESRF ID14-4 beam line at 
100 K on a Q315r ADSC CCD detector at 0.97372 Å. The data were indexed and 
scaled using XDS (247). A molecular replacement solution was obtained using the 
wildtype CFH19-20 structure (PDB code 2G7I) (106) and a truncated NMR structure of 
OspE (without the loops) with an R-factor of 0.3. After successive rounds of building 
with Coot (244) and refinement with REFMAC (242,243) or PHENIX (245), we 
could identify one OspE molecule bound to a single CFH19-20. The loops were 
modeled during real-space refinement using “phenix.refine” software without any 
applied restraints. The final R-factors (Rwork/Rfree) of the refined complex structure 
were 19.3/25.5 % (shown in Table 1). The last refinement cycles were done using 
TLS parameters (9 TLS groups). In the Ramachandran plot 94.0% of the residues in 
the structure were in the most favored regions. 
 CFHR14-5 was crystallized at 293 K from hanging drops in the presence of 2 
M ammonium sulphate, 0.1M sodium acetate at pH 4.6. The cube shaped crystals 
appeared within 5 days and were cryo-protected by 25% glycerol (supplemented by 
the mother liquor). The diffraction data (to 2.9Å) were collected at ESRF ID14-4 
beamline (248) at 100 K on a CCD ADSC Q315r detector at 0.979520 Å. The data 
was indexed and scaled using XDS (247). Using the structure of CFH19-20R1203A (PDB 
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code 3KZJ, study I) as a search model in PHASER(249) two molecules of CFHR14-
5 were identified in the asymmetric unit. After successive rounds of model building 
with Coot software and refinement in real space using ‘phenix.refine’ software (245) 
we could refine the structure to a higher precision (Rwork/Rfree = 0.20/0.26, also 
shown in Table 1). The last refinement cycles were done using TLS parameters. In the 
Ramachandran plot, 95% of the amino acid structures were within the most favoured 
region. The superpositions of different structures and structural illustrations were 
prepared using Pymol software (Schrödinger, Portland, USA). 
4.2.12 NMR Spectroscopy 
The NMR experiments were done by Jesper Oeemig under the supervision of Dr. 
Hideo Iwaï at Institute of Biotechnology, University of Helsinki. 
4.2.13 Microtiter plate assays with the patient AA 
The experiments with patient samples were done in collaboration with Dr. Mihály 
Józsi at Hans Knöll Institute, Jena, Germany (current address at Eötvös Loránd 
University, Budapest, Hungary).  
4.2.14 Calculation of the electrostatic potential of the structures 
Electrostatic potentials of the CFH19–20 wild type and the CFH19–20Q1139A and CFH19–
20R1203A mutant structures were calculated with APBS (250). Before calculation, the 
missing side chain atoms of some of the residues were added using COOT (244) on 
the basis of the location of the visible side chain atoms and electron density. APBS 
was run from PyMOL version 1.2 graphical interface. The program PyMOL (DeLano 
Scientific LLC) itself was used to generate the PQR file used to run APBS and add 
hydrogens to the structure. The positive isosurface contour was investigated after 
being displayed at +3 kT/e potential at Pymol. 
4.2.15 Curve fitting and statistical analyses 
Curve fitting was done using non-linear regression models implemented in GraphPad 
Prism®. For HPLC data Unicorn® program of ÄKTA® system was used to analyze 
the elution curves (GE Healthcare). The statistical analyzes were performed using 
Microsoft Excel® and GraphPad Prism®. The comparison of mean values was done 
using combination of F-tests and t-tests, and ANOVA (as per the availability of the 
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replicating data). The results were presented with mean using standard deviation to 
indicate the error. 
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5 RESULTS 
5.1 Both domains (19 and 20) of CFH are involved in C3b binding 
5.1.1 The interaction of the CFH mutants with C3d/C3b and Heparin 
Surprising results from previous studies (106,154) revealed that single point 
mutations in either the domain 19 or 20 of CFH lead to impaired binding of CFH19-20 
to C3b and C3d. We wanted to know whether both the domains 19 and 20 of CFH are 
involved in binding to C3d and C3b, since point mutations could cause loss-of-
function through secondary structural effects. In order to answer this question, we 
chose two representative mutant proteins with impaired C3d/C3b binding for further 
studies, one with a mutation in domain 19 and another with a mutation in domain 20. 
Mutation of the surface-exposed Q1139 to alanine in domain 19 led to one of the 
clearest losses of C3d/C3b binding (154). Therefore, we chose for the structural 
studies the CFH19-20Q1139A mutant protein as a representative of mutations in domain 
19 with impaired C3b binding. We selected another mutant protein to be CFH19-
20R1203A owing to its least proximity from domain 19. We also considered the fact that 
binding of the construct CFH19-20R1203A to C3d and C3b was highly impaired 
compared to that of the wild type CFH19–20 than the previously published set of 
mutant proteins (154). Our own binding studies confirmed that R1203A mutation 
developed impaired binding to C3d/C3b by the protein to a very prominent level (Fig 
1 of study I) 
We also studied the heparin binding profile of the mutants (used for the study 
I). It was already reported previously from our group that CFH19-20Q1139A had similar 
affinity towards heparin (154). However, CFH19-20R1203A gave a completely different 
heparin binding profile while compared to the WT CFH19-20 protein. The R1203A 
mutation introduced in CFH19-20 resulted in a loss of binding to the heparin column 
(Fig. 2 of study I) 
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5.1.2 The structures of the mutants CFH19-20Q1139A and CFH19-20R1203A  
The structures of the mutant proteins mentioned were solved to 2.0 and 1.65 Å 
resolution, respectively. The overall structures of both the mutant proteins were 
identical with the earlier reported wild type CFH19–20 (106) as seen by 
superimposing the Cα-atoms (Figure 5). The root mean square deviations (RMSD) of 
the mutant proteins (both CFH19-20Q1139A and CFH19-20R1203A) were extremely low 
when compared to the wild type CFH19–20 (study I).  
 
 We analysed the structures to determine if the mutations had effects on the 
side chains of the neighbouring residues of the mutated residue. None were observed, 
as only the side chain of the mutated residue was different. Even the main chain 
atoms of the mutated residues were seen to be in the same orientation (Fig. 4 of study 
I)  
Finally, we studied the changes in the surface electrostatics caused by the 
mutations. As expected on the basis of the lack of changes in the neighbouring 
residues and the nature of the mutation from charged to noncharged residue, no clear 
effect on surface electrostatic potential distribution was seen with the Q1139A 
mutation. On the contrary, a clear local change in terms of surface electrostatic 
potential occurred at the site of the R1203A mutation (Fig. 5 study I). This change 
was restricted to the surface area around the side chain of the mutated residue. Taken 
together, the Q1139A and R1203A mutations caused no changes other than the 
Figure. 6. The Crystal structures of CFH19-20   mutants 
superposed with CFH19-20WT 
The X-ray crystal structures of CFH19-20Q1139A
 
 
(Pdb code: 3KXV) and CFH19-20R1203A   (Pdb code: 3KZJ) 
superposed on CFH19-20WT structure (Pdb code: 2G7I). 
The CFH19-20WT  is in Grey, CFH19-20Q1139A   in light violet, 
and CFH19-20R1203Ain slate colour. 
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mutations in the structure despite their clear effect on binding of CFH19–20 to C3d 
and C3b. This indicated that both domains 19 and 20 of CFH are involved in binding 
to C3d part of C3b. 
5.2 A bigamic interaction of CFH revealed 
5.2.1 The CFH19-20:C3d structure 
Earlier attempts to crystallise CFH19-20WT coupled with its several ligands repeatedly 
yielded on only CFH19-20WT crystals. We noticed that CFH19-20 readily crystallises 
whenever it is present in high concentration with ammonium sulphate. Accordingly, it 
was challenging to obtain crystals of CFH19-20 in complex with any other ligands. We 
decided then to find out a mutant of CFH19-20 that did not form crystals readily by 
doing a small experiment of crystallising different CFH19-20 mutants in the presence of 
2M ammonium sulphate (Table 2). The CFH19-20D1119G/Q1139A was the mutant that did 
not crystallise (Table 2). Based on these results, we used the CFH19-20D1119G/Q1139A 
mutant for our experiments attempting to solve structures of protein complexes of 
CFH19-20.  
 
  
Figure 7. The crystal structure of CFH19-
20D1119G/Q1139A:C3d complex. The CFH19-20 mutant is 
in gray colour and C3d is in light blue.  
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We solved the CFH19-20D1119G/Q1139A:C3d structure (study II), which was 
initially determined by molecular replacement with C3d at 3.8 Å but refined against a 
higher-resolution dataset at 2.3Å. The asymmetric unit of the structure revealed a 
surprising CFH19–20:(C3d)2 heterotrimer (Figure 7) where two distinct sites on a single 
CFH19–20 molecule bind two separate C3ds in different ways and at different sites of 
C3d. The overall structures of both C3d molecules are unchanged (RMSD = 0.32Å, 
Figure 8). Both binding sites on C3d are far from the thioester site used for covalent 
attachment of C3b to targets (Fig. 1A of study II). 
 One of the interfaces (the CFH20 site) is formed by the arginine rich tip of the 
domain 20, which binds in a strongly electrostatic manner into a negatively charged 
pocket on the concave top of the helical bundle of C3d (Fig. 1B, Fig. S2 A,C of study 
II). The side chain of R1203 on CFH20 forms an ion pair with C3d E1153 located in 
the electronegative pocket of C3d. The total buried surface area of 490 Å2 includes 
three ion pairs and an extensive ionic network (Fig. S2 B,D of study II). The local 
changes in the loops around the CFH20 site, when compared to structure of CFH19-20 
only, are as follows: Lys1188 turns 180° to point towards C3d, and T1184 and R1171 
pack against C3d. Another interface (the CFH19 site) of CFH19-20:C3d interaction is 
larger (620 Å2) and less charged (Fig. 1C and Fig. S2B of study II). This interface is 
formed by residues from both CFH19 and CFH20 that bind to the side of C3d at 
helices 104–118 and 170–189 and the Pro121 loop (the C3dFH19 site) (Fig. 1C and 
Fig. S2D of study II). The C3dFH20 site was observed to be partially buried in the full 
C3b molecule (Fig. 1B of study II). 
Figure 8. Structural alignment 
between the C3d molecule in 
CFH19-20:C3d structure (PDB code: 
2XQW, light blue in colour) and the 
C3d structure solved alone (PDB 
code: 1C3D, olive in colour).  
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5.2.2 Confirmation of the physiological relevance of the structure 
We also modeled back the two mutated side chains D1119 and Q1139 to the crystal 
structure (Fig. S5 of study II). This indicated that D1139 would hydrogen bond to the 
I115 carbonyl group and Ser171, and Asp1119 would form an intermolecular helix 
cap with C3d (Fig. S5 of study II). The mutant bound C3d more poorly than WT, 
which was observed earlier (154). 
Functional effects of some of the point mutations in the “CFH19 C3b site” 
(D1119G, Q1139A, and K1188A) or the “CFH20 C3b site” (R1182S/A, W1183L, 
T1184R, and R1203A) have been reported to lead to reduced C3d/C3b binding 
(106,154,156) (study I and Fig. 2A and Table 1 of study II). These results verified 
the two binding sites we found in the crystal structure. In order to further verify the 
two binding sites, we tested the binding of seven C3dg mutants to CFH19–20. Both the 
mutations in the C3dFH19 site (E117A and D122A) and all four mutations in the 
C3dFH20 site (D36A, E160A, D163A, and K291A) significantly reduced the affinity of 
the interaction (Fig. 2B–D of study II), whereas the control (E37A) had no effect.  
5.3 Borrelia burgdorferi binds CFH20 to evade complement 
5.3.1 The Borrelial OspE structure 
The solution structure of OspE was solved by NMR spectroscopy (Table 1, Fig 1a of 
study III). Residues 42-171 of OspE form a globular single-domain with a backbone 
RMSD of approximately 0.38 Å between the different NMR models indicating a very 
well defined and stable structure. The OspE core domain has a rigid α+β fold of eight 
β-strands and two short α-helices arranged in a repeating topology of four β-strands 
followed by an α-helix (β1- β2- β3- β4-αI- β5- β6- β7- β8-αII). The β -strands form 
antiparallel β-sheets where β1- β4 and β5- β8 are orientated almost perpendicularly. 
β1 and β8 are held together by hydrogen bonds thus forming a disoriented asymmetric 
β-barrel. It can be concluded as a β-barrel with one uniform and another non-uniform 
side. The β2 and β6 strands are highly twisted and deviate from the formation of 
classic β-barrel strands. β1, β2, and β6 are fairly long strands (10, 12 and 11 residues 
respectively) and β5 along with β8 are the smallest β-strands (6 residues each).  
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The N-terminal region (residues 20-41) of OspE is structurally flexible as 
shown by superimposition of residues 42-171 from 20 NMR structures (Figure 9). 
The 15N relaxation data of OspE (Supplemental Fig. 2 of study III) also shows that 
these residues are moving freely.  
5.3.2 The CFH19-20:OspE complex structure 
Optimization of heterodimer formation by gel filtration analysis of OspE and CFH19-20  
(Fig. 2a of study III) enabled us to crystallize OspE in complex with CFH19-20. Using 
the optimized 1:1 molar ratio of the proteins (Supplemental Fig 1b of study III) we 
obtained rod shaped co-crystals (Figure 10) of OspE and CFH19-20. The crystal 
structure of the OspE:CFH19-20 complex was solved at 2.83 Å resolution (Table 2, 
Figure 6) using our previously solved CFH19-20 structure (106) and the NMR structure 
of OspE (described before) as the initial models in molecular replacement. In the 
complex, OspE binds to domain 20 of CFH with a contact surface area of 691 Å. The 
complex is held together by an E68OspE-R1182CFH-D73OspE ion triple, which is also 
hold together by a sulfate group forming an R1182CFH-SO4 --R66OspE ion triple, while 
R1182 CFH also forms an ion-pair with E1198CFH (Fig. 2c and 2d of study III). These 
interactions form the top part of a pocket for W1183CFH, which makes hydrophobic 
contacts with the aliphatic side chain of R1182CFH and with the backbone atoms 
around G75OspE and A83OspE.  
Figure 9. The NMR ensemble of 
20 different energy-minimised 
NMR structures of OspE. The NMR 
structures are superposed with the 
backbone of its globular domain 
(res 42-171) 
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The OspE structure in solution (NMR) and in complex with CFH19-20 (X-ray) 
was very similar (backbone RMSD of 1.43 Å/Cα) (Supplemental Fig. 7a of study 
III). The structure of CFH19-20 in complex with OspE was also practically identical to 
the published structures of CFH19-20 in homo-tetramers (106) (backbone RMSD 1.43 
Å/Cα) or in the CFH19-20:C3d complex (study II) (backbone RMSD 1.15 Å/Cα) 
(Supplemental Fig. 7b of study III). The sulfate ion found in the OspE:FH19-20 
interface did not affect the orientation of the side chains, not even R1182CFH19-20 in its 
close vicinity (Supplemental Fig. 8a,b of study III). When the region of OspE close to 
the sulfate ion was compared between the NMR ensemble and the crystal complex 
structure it was observed that orientation of E68 was similar while that of R66 was 
slightly different, most probably due to a hydrogen bond between the NH2 of R66OspE 
and O of R1182CFH19-20. 
5.3.3 The NMR chemical shift assay confirms the interaction site to be 
physiological 
To further verify the existence of the observed interface between OspE and CFH19-20 
under physiological conditions, or at least in fluid phase, we analyzed chemical shift 
perturbations in the NMR spectrum of OspE upon addition of saturating 
concentrations of wild type CFH19-20 (Fig. 3a, Supplemental Fig. 3 study III). The 
Figure 10. The X-ray crystal structure of 
CFH19-20:OspE complex. The OspE 
molecule is shown in lemon and CFH19-
20   in gray colour.  Inset: Rod type 
crystal obtained for the complex 
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residues of OspE that shifted most (>0.4 ppm) are clustered on β-strands 1-4 that form 
the core of the OspE:FH19-20 interface in the crystal structure (Fig. 3b). Of the nine 
OspE residues involved in hydrogen bonding, six could be assigned in the assay and 
five of those were among the residues that shifted most (>0.4 ppm) (Table 3 of study 
III). The other three residues involved in binding (R66OspE, G80OspE and T84OspE) 
could not be assigned in the spectra of the CFH19-20 bound OspE, probably due to 
large changes in the microenvironment caused by formation of the complex. We also 
confirmed the interface of CFH19-20 and OspE from the CFH19-20 side using mutants of 
CFH19-20 results of which have been reported elsewhere (226). 
5.4 Molecular basis for autoimmunity against CFH in aHUS 
5.4.1 The autoantibody binding site on CFH19-20  
Binding of IgG from sera of eleven aHUS patient with AA against CFH (CFH-AA) to 
14 CFH19-20 mutants was tested (Fig 2A of study IV). Binding of IgG of all the tested 
patients was diminished in case of the L1189R mutant (less than 70% of binding to 
the WT CFH19-20). Binding of IgG from nine patients was diminished to the CFH19-
20E1198A mutant. IgG from seven to eight patients were found to have impaired binding 
to the CFH19-20 constructs with mutations T1184R, K1186A, and K1188A while 
binding of IgG of only one to two patients was impaired to the mutants CFH19-
20Q1139A, CFH19-20R1182A, or CFH19-20W1183L (Fig. 2B of study IV). The binding of the 
patient IgG to WT CFH19-20 and to the mutants CFH19-20D1119G, CFH19-20W1157L, CFH19-
20R1203A, CFH19-20R1206A, CFH19-20R1210A, and CFH19-20R1215Q was similar (Fig 2B of 
study IV).  
The monoclonal antibody C18, which had been shown previously to have an 
epitope overlapping with that of the CFH-AAs (218,221) bound to the exact same site 
on the CFH C-terminus (Fig. 2A of study IV) 
Surprisingly, the two residues that are different in CFH19-20 and CFHR14-5 
were found to be located beneath the CFH-AA site. We therefore studied whether the 
small difference in the amino acid sequence had an influence on binding of the AA. 
IgG from ten out of the six tested patient samples bound similarly to CFH, CFH19-20, 
and CFHR14-5 (Fig. 3 of study IV) while binding of one of the samples (patient 9) 
was clearly impaired to CFHR14-5 when compared to CFH or CFH19-20 (Fig. 3 of 
study IV). These results, in agreement with previous data (217,220), indicated that 
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the conformation of the CFH-AA site could be slightly different in CFH domain 20 
and CFHR domain 5 despite of the difference in only two buried amino acids.  
5.4.2 The global structure of C-terminus of CFHR1 
To detect possible differences in the identified CFH-AA site on CFH19-20 and the 
corresponding site of CHFR1 we used X-ray crystallography to solve the structure of 
CFHR14-5. The structure of CFHR14-5 was obtained as a homodimer at 2.9 Å 
resolution (Table 1) from a different space group (a hexagonal P622) than the 
previously published CFH19-20 structures (tetragonal I4122) (Table 1 of study I and 
(106), but the structures aligned very well with each other (Fig. 4A of study I) and 
the region containing the mutations S1191L and V1197A was only slightly different 
(Fig. 5C of study IV). RMSD of 113 aligned Cα atoms was only 0.5-1.1 Å upon 
alignment of the CFHR14-5 structure with the previously published structures of 
CFH19-20 solved as homotetramers (106) (0.5 Å) or in complex with C3d (study II) (1 
Å) or Borrelial OspE protein (study III) (1.1 Å). This indicates that the structures 
were practically identical (Figure 15).  
Figure 11. The structures of wild type 
CFH19-20 and CFR14-5 superposed. Both 
CFH19-20 and CFR14-5 are represented by 
cartoon diagrams. CFH19-20 is in gray and 
CFR14-5 is in orange. The CFH-AA site  is 
marked. 
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The structures of CFH19-20 and CFHR14-5 were seemingly identical. However, 
the conformation of the CFH-AA site on CFHR14-5 was somewhat different from that 
on CFH19-20 (Figure 11) since both the backbone and loops forming the site (R281-
K287 or CFHR1 and R1182-K1188 of CFH, respectively) had a slightly different 
orientation (Fig. 5D of study IV). The main difference in the backbone is a short 
alpha-helix in the loop of CFHR14-5 while no prominent helix was seen in the 
aforementioned zone in any of the previously solved structures of CFH19-20. The 
orientation of some of the side chains was also clearly different as all the residues 
from R281 through K287 of CFHR14-5 were at least 5 Å apart from the location of 
side chains of the corresponding residues of CFH19-20 (from R1182 through K1188) 
(Fig 5D of study IV). In order to exclude potential misrepresentation of X-ray 
diffraction data of the CFH-AA site, we also compared the electron density maps 
(2Fo-Fc) of R1182-K1188 of CFH19-20 (106) and R281-K287 of CFHR14-5 (Fig. 6 of 
study IV). Clearly the model of CFHR14-5, but not of CFH19-20 fits very well with the 
electron density map of CFHR14-5 for the mentioned region (Fig. 6A and B of study 
IV) while the corresponding region in the model of CFH19-20, but not of CFHR14-5, fit 
well with the electron density map of CFH19-20 (Fig. 6C and D of study IV).  
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6 DISCUSSION 
 
In this thesis, X-ray crystallography and accompanying structural studies were used to 
unravel the molecular mechanisms regarding the involvement of two C-terminal 
domains of CFH in complement activation.  The molecular basis of the role of CFH 
C-terminus in the target discrimination of self or non-self structures by AP was 
revealed in the first two studies of this thesis (study I and study II). In these studies 
we solved the structures of two mutants of CFH19-20 (one of them being an aHUS 
associated mutation) and the structure of CFH19-20 in complex with C3d. The 
structural basis of the process of complement evasion by microbes binding to CFH C-
terminus was explained by solving the crystal structure of CFH19-20 in complex with a 
borrelial surface protein OspE (study III). We also proposed a novel explanation for 
the formation of CFH-AA in aHUS patients lacking CFHR1 by mapping the AA 
binding site on CFH and solving the structure of CFHR1 C-terminus (study IV). 
6.1 Molecular basis for the self non-self discrimination by AP  
The primary function of the C-terminus of CFH has been established to be the 
discrimination between activators and non-activators, i.e. protection of host cells from 
complement mediated damage while allowing activation on foreign targets. The 
importance of this region is very well documented by the onset of the systemic 
disease aHUS, primarily associated with point mutations in the C-terminus of CFH. 
The mutations in CFH are primarily located in the last two domains (183). CFH is a 
pattern-recognition regulator that will act on any surface, including the extracellular 
matrix, which carries host-specific molecular signatures.  It has been shown earlier 
that negatively charged surfaces bearing SA and heparin were critical for protection 
of erythrocytes from complement attack by CFH (39,110,251). Later, the self and 
non-self discrimination of C3b deposited surfaces was reported to be mediated by the 
polyanion-binding site on CFH (40). Eventually, C3d/C3b and heparin binding sites 
were mapped on the CFH19-20 region (103,158,166) by the 1990s. The interaction 
between C3b and CFH is important for the proper complement function as 
demonstrated by the dramatic clinical effects caused by mutations interfering with this 
interaction in aHUS.  
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Earlier several mutations in domain 20 of CFH were known to impair binding 
of CFH to either C3d/C3b or heparin or both, which led to the conclusive evidence of 
CFH20 being functional in CFH binding to both heparin and cell-bound C3d/C3b. 
Since none of the CFH19 mutations impaired heparin or endothelial cell binding, but 
CFH20 mutations did (154,156), it was likely that the binding site for heparin and 
endothelial cells is limited to domain 20, which is also supported by other reports 
(252). In study I of this thesis impaired binding to heparin was seen with the R1203A 
mutation in domain 20 but not with Q1139A in domain 19, fitting well with earlier 
data.  
On the basis of earlier reports, the role of domain 19 in binding of the C-
terminus of CFH to C3d/C3b was not evident, as only the domain 20 seemed to be 
important. A role for domain 19 was, however, hinted by a few CFH19 mutations 
leading to impaired binding of CFH19–20 to C3d and/or C3b (154,156). The study I in 
this thesis shows that the Q1139A mutation in domain 19 also leads to impairment in 
binding of CFH19–20 to C3d and especially C3b, similarly to the R1203A mutation in 
domain 20. The X-ray crystal structure of both the CFH19-20Q1139A and CFH19-20R1203A 
mutants showed that only minor and local changes are caused to the structure of 
CFH19-20 by the mutations. This led us to conclude that any effect on binding must 
therefore be due to the local changes in the CFH structure. The documented loss-of-
function by the mutations Q1139A and R1203A can thus be conclusively attributed to 
the absence of the side chains of these residues at the binding interface and we 
concluded that both residues Q1139 and R1203, and thus both domains 19 and 
domain 20 of CFH are involved in binding C3d and C3b. Though the involvement of 
CFH20 in aHUS was understood, the study I in this thesis also explains why 
mutations in domain 19 could also lead to impaired regulation of AP on surfaces 
leading to aHUS.  
Our study II revealed that the domain 20 of CFH has a binding site to 
C3d/C3b (Figure 7) and it has previously been shown to have a site for heparin, in the 
same zone as well (Fig. 3C of study II). Both the sites on domain 20 could in 
principle be involved in target discrimination. The mutual importance of these two 
sites in target discrimination is not evident. However, there are three key findings to 
evaluate the role of heparin vs C3d/C3b binding by domain 20. First, based on our 
results while CFH19 is bound to C3b, CFH20 can simultaneously bind to either the cell 
surface polyanions or another C3d or C3dg molecule (Fig. 3 of study II). There 
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seems to be steric hindrances for CFH19-20 to bind two C3b molecules (one via 
domain 19 and another via domain 20) but it is surely possible to bind one C3b via 
domain 19 and C3d via domain 20 (Fig. S3 of study II). Second, there are aHUS-
associated mutations in the thioester domain of C3 at exactly the binding site for 
domain 20 of CFH. Since these mutations (or the regions around those) are not known 
to have any other functions it seems that disruption of C3d binding by domain 20 of 
CFH could lead to aHUS. Third, we have noticed that heparin inhibits binding of C3d 
to the aHUS mutant CFH19–20T1184R (a mutant associated with aHUS) even more than 
to CFH19Del–20  with mutations of three residues involved in the binding of CFH19 to 
C3b (study II) suggesting that the abnormally strong heparin binding by this mutant 
could interfere with function of CFH, e.g. by interfering with C3d binding by the 
CFH20 site, thus leading to aHUS. This has not been directly shown but the result 
indicates that strong heparin binding without C3b/C3d binding is not enough for 
efficient target discrimination by CFH. In conclusion, it is possible and even likely 
that CFH20 binding to both heparin and C3d is important for target discrimination and 
that loss of either of the interactions could lead to aHUS. 
One question which surfaced after our study II concerned the explanation of 
the CFH20 binding to C3d and the presence of aHUS mutations in CFH20 and the 
corresponding sites on C3b/C3d. If CFH19 is considered to be the only C3b binding 
site within CFH19-20, as suggested by Morgan et al. (162), the explanation of the 
presence of aHUS mutations in C3dFH20 binding site on as well as its binding behavior 
with C3d could not be explained. In addition to the model presented in the study II it 
is also possible that a conformational change of C3b upon binding to a non-activator 
surface exposed the C3dFH20 binding site. There is, however, no structural evidence 
for this. 
Intriguingly, in our model of the C3b:CFH19–CFH20:C3d complex, the two 
thioester sites on C3d and C3b both face to the putative cell surface (Fig. 5 of study 
III). This is consistent with C3d (or iC3b) recruiting CFH on non-activator surfaces 
as  proposed in our study II. Binding of the CFH20 site to C3d or iC3b could thus 
replace binding of CFH20 to non-activator surface polyanions, further explaining why 
the C3d and polyanion sites overlap on CFH20. Thus, our cumulative results in study 
I and study II suggest a comprehensive molecular mechanism for target 
discrimination of AP and provide evidence for negative feedback control of activation 
on non-activator i.e. host cell surfaces and extracellular matrix. This model explains 
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widely, if not even fully, the location of aHUS point mutations (http://www.fh-
hus.org) in CFH19–20 and the mutations within the C3d part of C3b. Mutations in 
CFH19 affect C3b binding (154), and mutations in CFH20 affect, variously, 
glycosaminoglycan binding and/or C3d binding. All aHUS mutations in the C3d 
domain affect either CFH19 or CFH20 binding to C3d/C3b (154), which explains how 
all these mutations in CFH reduce control of C3b on non-activator surfaces, leading to 
the onset of the disease aHUS. 
6.2 The microbial complement evasion: a molecular perspective 
In our study III we resolved the structural basis of complement evasion by Borrelia 
burgdorferi via OspE. This study also provided information on microbial complement 
evasion in general. An extensive study on microbial binding of CFH19-20 (226) 
elucidates a multifaceted microbial angle of the story. The study III of this thesis 
revealed the structure of borrelial OspE in complex with CFH19-20, identified the 
binding surfaces and residues used for the interaction between OspE and host CFH, 
and explained how CFH is recruited by OspE onto the borrelial surface. A molecular 
model (Fig. 5 of study III) also revealed that OspE-bound CFH is sterically able to 
bind the central complement component C3b on the same surface.  
Our structure, however, contrasts with the previously suggested coiled coil 
structure for OspE (253). It has an 8-stranded up-down β-barrel globular structure 
(residues 42-171) linked to the membrane by a very flexible amino acid tail (Fig. 1 of 
study III), a fold found in SALP family, and primarily in the families of ‘Nucleic 
acid binding proteins’ and ‘Fatty acid binding proteins’ (Figure S5 of study III). The 
fold of the globular domain seems to be stable and fairly rigid since RMSD of the 
globular domain of the 20 NMR structures was only 0.38±0.05 Å for the backbone 
atoms and the structures of the CFH19-20:OspE crystal structure and the NMR 
structure of OspE were very similar (RMSD of 1.43 Å for Cα atoms). The flexibility 
of the tail can be explained by the tethering phenomenon that would naturally be 
useful for a bacterial surface protein. But why does the globular part of OspE needs to 
be so rigid? One possibility is that a rigid domain remains stable in variable molecular 
environments, allowing binding of CFH in all microenvironments of human and tick 
body. Alternatively, it could be useful if the fold did not change upon binding to a 
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ligand since such an opening would allow new antigenic epitopes to be revealed – a 
phenomenon that would be harmful for the bacterium.  
In our OspE:CFH19-20 structure, we could see that four residues (R1182, 
W1183, E1198, and R1215) in the CFH C-terminus play a key role in the interaction. 
The central role of these residues is supported by the chemical shift perturbations in 
the NMR spectrum of OspE upon addition of saturating concentrations of wild type 
CFH19-20 and by the competition-binding assay with 14 mutant CFH19-20 proteins 
(226). The study III found the previously proposed theory of multiple lysine residues 
in OspE being functional in CFH binding (123) to be contradictory since in our 
OspE:CFH19-20 structure there were no lysines in the interface. The results in study 
III also explain the previous data with deletion mutants of P21, an OspE homolog, 
(123) since the deletions used by Alitalo et al eliminated the beta strands involved in 
the interaction.  
It has been earlier shown that binding of CFH is essential for B. burgdorferi to 
survive in human serum, and that OspE (i.e. BbCRASP3-5) and BbCRASP1 are 
needed for this survival (122,254). It is obvious that the microbe benefits from the 
recruitment of host CFH onto the microbial surface since CFH acts as a cofactor for 
factor I in the degradation process of the central complement component C3b needed 
for both opsonization and propagation of the complement cascade to form membrane 
attack complexes. Therefore it is easy to understand that acquisition of host CFH onto 
borrelia correlates strictly with survival of the spirochetes in non-immune serum or 
blood, as observed earlier (255). The importance of OspE vs BbCRASP-1 mediated 
binding of CFH is, however, not known. The importance of OspE in immune evasion 
is supported by expression of OspE in vivo as judged by the emergence of anti-OspE 
antibodies in convalescent sera of patients with borreliosis. In addition, all the known 
strains of B. burgdorferi s.s. and B. garinii have at least one gene of OspE and most 
strains have several OspE paralogs that are homologous enough to take a similar fold 
(Fig.4 of study III).  
6.3 Link between the CFHR1 deficiency and the AI-aHUS puzzle 
AI-aHUS is a unique autoimmune disease associated with the deficiency of CFHR1 (a 
protein homologous to parts of CFH, see section 2.4.3). The reason for the presence 
of anti- CFH-AA in the absence of CFHR-1 in AI-aHUS has been a mystery. The 
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study IV shows that the autoantigenic epitope on CFH, i.e. where CFH-AA bind to, 
form a cluster on domain 20 of the protein. This cluster is adjacent to the heparin and 
common microbial binding site on domain 20 of CFH (Fig. 2 of study IV) and also in 
close proximity to the two buried residues that are different in the C-terminal domains 
of CFH and CFHR1. It has previously been observed that CFH-AA from an AI-aHUS 
patient binds to CFH19-20 and CFHR1 differently, which is a phenomenon observed 
for full-length CFH as well (217,220) (see Figure 3 of study IV). We found minor 
differences in the X-ray crystal structures of the loop forming the auto-antigenic 
epitope on CFH and CFHR1 (Figure 7). Keeping in mind that the CFHR1 deficiency 
is found in nearly all the AI-aHUS patients, it is possible to conclude that CFHR1 
plays a role in initiating and/or maintaining tolerance to CFH. The findings in study 
IV suggest that the structural difference in the loop forming the auto-antigenic epitope 
on the C-terminus of CFH and CFHR1 is the key to the puzzle of CFHR1 association 
and CFH tolerance.  
The patients from whom the sera for the study IV were taken from were from 
Germany and Hungary. Ethnically, the population represents fairly well a Central 
European population and genetic background but not worldwide distribution of, for 
example, major histocompatibility complex (MHC) genes involved in cellular 
immunity. It remains to be seen if patients from other parts of the world also exhibit 
the same behavior in terms of CFH and CFHR1 binding. 
Could the clustering of the CFH-AA epitope result from structurally remote 
effects of the mutations introduced to CFH19-20? Prior studies (study I) (226,256) 
confirmed that CFH19-20 mutations do not contribute to any prominent change in the 
domain fold of CFH via X-ray crystallography and circular dichroism studies. This 
indicates that the reduced CFH-AA binding in the epitope mapping study (Figure 2 of 
study IV) using the CFH19-20 mutants is not caused by any folding anomaly of the 
mutants but by a real clustering of the epitopes to a single loop on domain 20 of CFH 
(Figure 11). However, the CFH-AA binding analyses were all performed in a way that 
the mutants were coated to a plastic surface. This results in a possibility that binding 
of various mutants to the surface could be different and thus cause systematic error in 
the binding site mapping. The main reason why the autoantigenic epitope is real and 
not an artifact is the functional difference between the two terminal domains of CFH 
and CFHR1.  The exact similarity (sequence and structure) of the CFH19 and CFHR14 
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leaves only the option of CFH20 and CFHR15 to be different enough to establish the 
clinical disease. 
It has already been shown that molecular pathogenesis of aHUS involves the 
loss of CFH binding either to C3b or to host cell surface structures such as GAGs or 
heparin (105,106,154,196,209,  and study II). It is also known that AA from some 
patients impair CFH binding to C3b or to the cell surface structures (218). The 
impaired binding of CFH to either the cell surface structures or C3b influences the 
protection of the plasma exposed endothelial cells, thrombocytes, and red cells in 
aHUS (205). The location of the CFH-AA binding site we identified on domain 20 
(Figure 2 of study IV) indicates that the AA are likely to block binding of 
GAGs/heparin to CFH, owing to its partial overlap with the GAG binding site on 
CFH20 (Figure 12). It is also possible that CFH-AAs interfere with C3b binding of 
CFH as well owing to the large size of IgG. This is supported by the binding studies 
with C18 mAb against domain 20 of CFH (218).  
The risk for CFH-AA in the absence of CFHR1 is very high (Odds ratio over 
400) (215). This motivated us to study the structural differences in the CFH-AA site 
in CFH domain 20 and the corresponding site on CFHR1 domain 5 (which are 
different by just 2 residues). Since only two residues are different in CFHR14-5 and 
CFH19-20, it is not surprising that the crystal structures of CFHR14-5 and CFH19-20 are 
so similar. However, a minor difference was identified specifically at the CFH-AA 
Figure 12. Surface representation of the domains 19 and 20 
of CFH showing the CFH-AA site (light blue), 
heparin/endothelial cell binding site (purple) and the common 
microbial binding site (dark blue). 
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site (Fig. 5 and Fig. 6 of study IV). The results obtained in study IV provided a 
structural basis to the phenomenon of CFHR1 deficiency in AI-aHUS. The 
hemolysis-inducing aHUS related mutation W1183L (220,257) of CFH being located 
in the centre of the CFH-AA binding site confirms the importance of the site in host 
cell protection.  
The issue of the crystal structure being an artifact has been discussed 
extensively in the study IV. Structurally, the most important fact that there were no 
direct contacts between the residues of the CFH-AA site (R281-L288) and the 
molecule in the neighboring crystal cell (Figure 13) made it unlikely to be an artifact. 
Functionally, the most important argument against the structure being an artifact is 
that the fusion proteins CFH1-18/CFHR14-5 or CFHR11-3/CFH19-20 associated with 
aHUS have different functions from normal CFH and CFHR1 (210,211,258). 
Together with other arguments given in the discussion of study IV, the 
functional difference between CFH20 and CFHR15 is likely to be in their ability to 
bind to heparin/GAGs on self cells (154,252) and the autoantibodies would naturally 
disrupt this interaction.  
Figure 13. The CFHR14-5 structure shown along with its symmetry (crystal) mates 
and the corresponding crystal cell. CFHR14-5 with the CFH-AA site is shown in 
orange and its symmetry mates in olive colour.  
  
 Inset: close-up showing the CFH-AA site (also highlighted by line representation). 
The closest distance from its neighbour is shown by a dotted line (4.0 Å) 
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A novel hypothesis has been proposed which explains the association between 
formation of CFH-AA and deficiency of CFHR1 (Fig. 7 of study IV). Briefly, the 
model is based on the subtle conformational difference in the CFH-AA binding region 
of CFH and CFHR1. We think that the CFH-AA region of CFH could adopt an 
alternate conformation upon binding a microbial molecule to the adjacent microbial 
binding site on CFH domain 20, resulting in formation of a neo-epitope, identical to 
the natural CFHR15. For a CFHR1 non-deficient healthy individual, CFHR1 antigen 
would result in central tolerance to CFHR1 (and CFH domains 18-20). But in case of 
a homozygous CFHR1 deficient human, the alternative conformation naturally 
occurring in CFHR1 would not be introduced to the immature B-cells resulting in 
emergence of CFH-AA upon e.g. a microbial ligand binding to CFH20. However, as 
far as we know, all the patients with AI-aHUS do not have a history of a recent 
infection and there are even some cases without CFHR1 deficiency. Our model 
explains most issues in the autoimmunization but not all of them. This is likely to be 
caused by variability in the mechanism that could also explain some variety in the 
binding sites of antibodies against other parts of CFH than the C-terminus (219). 
Though the formation of a co-neoepitope in presence of a ligand of CFH and shared 
by it (Fig. 7 of study IV) leading to the formation of AA against CFH can be an 
explanation of the AI-aHUS pathogenesis as well, the theory does not explain the 
CFHR1 deficiency in AI-aHUS patients. If we consider that an altered self-molecule 
or an exogenous molecule forms the neoepitope in CFH20, the concept still fails to 
explain the issue of CFHR1 deficiency. Additionally, there have been reported cases 
of microbial infection to the patients preceding AI-aHUS, the explanation of which 
remains elusive as well. 
In conclusion, we found that in case of AI-aHUS, the AA bind to a common 
epitope that is adjacent to the polyanionic and microbial binding site on CFH20. The 
conformation of this epitope is slightly different in CFH and CFHR1, introducing a 
structural explanation why nearly all AI-aHUS patients are deficient of CFHR1.  The 
results also do indicate that a just a subtle conformational change of the antigen has 
the potential to lead to an autoimmune disease.  
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6.4 Structural analyses of various structures of CFH19-20 
In this thesis there are all together five solved structures of the C-terminus of CFH (or 
CFHR1, red in Figure 14). Superimposition and RMSD analyses point very clearly to 
the fact that the distal end of CFH is structurally very coherent even in very different 
conditions. The rigidity of the structure can be assessed from the fact that almost 8 
different structures (Figure 14) has an RMSD of around 1Å only while superposed on 
each other (Figure 15). Domain 19 and domain 20 of CFH has been always seen 
constantly with a ~32° angle in relative to each other’s axis, even in the CFH18-20 
structure (259). aHUS mutations (eg CFH19-20R1203A) (study I), binding to C3d/C3b 
(study I), binding to microbial proteins (study I) could not induce any prominent 
structural change in the structure of CFH19-20. Not surprisingly, rigidity of CFH19-20 
structure has also been recognized by at least one other group (259).  
 
 
 
Figure 15. The CFHR14-5 (orange) structure shown along with 
its 8 other CFH19-20 homologues. The WT CFH19-20 structure is 
shown in gray colour. 
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Although the structures of CFH19-20 have been observed to be rigid in nature, an 
unexpected kink is seen between the domain 18 and 19 of CFH (259). The domain 18 
of CFH has been noticed to be tilted by ~122° with respect to the long axis of CFH19, 
and by ~151° along the axis CFH19-20.  
 
To visually compare the surface charges of WT CFH19-20, CFHR14-5, and 
CFH19-20R1203A, the charge distribution was first calculated using APBS and plotted on 
the WT CFH19-20 structure (Fig. 5 of study I and Fig. 6 of study IV). As expected, we 
noticed distinguishable difference in the distribution of the contour of the positive 
isosurface in case of CFH19-20 and CFH19-20R1203A as displayed in the figure. Though 
not so prominent, we also noticed deficiency of an electronegative pocket in case of 
CFHR14-5 as well. 
6.5 Crystal artifacts, the pinch of salt 
With the advent of the high throughput system of solving molecular structures, the 
rate of structure (protein) solving has gone up by several fold, which have 
revolutionised the way of understanding molecular interactions which happen in our 
body continuously. However, it is worth mentioning here that very often the 
crystallising conditions of the proteins (or any other molecules) are not very 
physiological, thus bringing potential misguidance to the very basic reason of 
structure solving. All of our structures of CFH and CFHR1 were solved in the 
presence of ~2M ammonium sulphate, which is not close to physiological conditions. 
Therefore, it is important to emphasize that the structures shown in this thesis have 
been verified by biochemical and immunological methods as well as has been 
possible.  
We had to disregard an interface of CFH:C3d indicated in the CFH19-20:C3d 
structure solved by us (Pdb id: 2XQW, study II). Our previous binding studies clearly 
showed that it could not be the binding interface between C3d/C3b and CFH19-20 
(106,154). 
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6.6 Conclusions and future prospects  
In conclusion, the C-terminal domains 19 and 20 of CFH actively work in order to 
differentiate between the self and non-self molecules in order to prevent complement 
attack against self-structures while defending successfully against microbes. The 
mechanism that controls this target discrimination was revealed at a molecular level, 
which paved the way to understanding the molecular implications of the aHUS 
mutations in the C-terminus of CFH. Molecular mimicry by microbes which imitates 
the polyanionic host structures, in order to evade the complement attack, was also 
demonstrated in atomic resolution using B. burgdorferi as a model. The results also 
shed new light on the pathogenesis of AI-aHUS by the epitope mapping of the CFH-
AA on the C-terminus of CFH and the molecular structure of CFHR1. All of these 
three separate molecular mechanisms involving the domains 19 and 20 of CFH were 
resolved to a high resolution in this thesis, thus increasing the understanding of aHUS 
disease established by complement malfunction, complement evasion by bacteria, and 
potentially also the process of autoimmunization in general.  
 The study of several newly solved structures (specifically different CFH19-20, 
Figure 14) structures have illustrated the process of target discrimination in detail. 
However, microbial exploitation of CFH as a complement evasion tool is still not 
understood extensively. We have made an attempt to understand it from the CFH19-20 
point of view in our recent publication (226). The successful vaccine (Bexsero) 
against Neisseiria meningitidis serogroup B with the factor H binding protein of the 
microbe has made the field of CFH binding by microbes extremely important in next 
generation vaccinology.  
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